Drug Name	Generic Drug Name	Indication	Application Status	Date Application Approved
Lucantic	ranihizumah	neovascular age-related macular degeneration (AMD) as per the Novartis	ADDDOVED	27/11/2012
Lucentis	ranibizumab	Pharmaceuticals Australia Pty Ltd protocol	APPROVED	27/11/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	2/07/2012
Cholecystokinin		for imaging of the biliary tract	APPROVED	12/09/2011
cholecystokinin	Kinevac/ Sincalide	imaging of the biliary tract	APPROVED	12/09/2011
cholecystokinin	Kinevac/ Sincalide	for use in nuclear medicine biliary studies	APPROVED	12/09/2011
Melatonin		sleep disturbance in children with severe disabilities	APPROVED	25/08/2011
Indocyanine Green		retinal angiography	APPROVED	13/09/2011
Cholecystokinin	Sincalide, Kinevac	for imaging of the biliary tract.	APPROVED	13/09/2011
cholecystekinin	Kinevac/ Sincalide	use in imaging of the biliary tract	APPROVED	13/09/2011
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	12/09/2011
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography.	APPROVED	12/09/2011
Indocyanine Green		during vitreo-retinal suegery and for intravenous injection to perform ICG angiography	APPROVED	12/09/2011
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography.	APPROVED	8/11/2011
Cholecystokinin	Sincalide, Kinevac	for nuclear medicine biliary studies.	APPROVED	14/11/2011
Mafenide 5%	Sulfamylon	for wound management of deep partial and full thickness burns to ears	APPROVED	13/09/2011
Mifepristone		To decrease the length of labour induction in cases of foetal anomalies, foetal death in utero or severe maternal illness in first and mid trimester of pregnancy	APPROVED	30/08/2011
Mifepristone		To decrease the length of labour induction in cases of foetal anomalies, foetal death in utero or severe maternal illness in first and mid trimester of pregnancy	APPROVED	30/08/2011
Mifepristone		To decrease the length of labour induction in cases of foetal anomalies, foetal death in utero or severe maternal illness in first and mid trimester of pregnancy	APPROVED	30/08/2011
Mifepristone		To decrease the length of labour induction in cases of foetal anomalies, foetal death in utero or severe maternal illness in first and mid trimester of pregnancy	APPROVED	30/08/2011
Mifepristone		To decrease the length of labour induction in cases of foetal anomalies, foetal death in utero or severe maternal illness in first and mid trimester of pregnancy	APPROVED	30/08/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011

		Termination of pregnancy where medical abortion is assessed clinically as the		
Mifepristone		most appropriate method for the woman, including when surgical abortion is	APPROVED	26/08/2011
Winepristone		not available.	711110125	20,00,2011
		Termination of pregnancy where medical abortion is assessed clinically as the		
Mifepristone		most appropriate method for the woman, including when surgical abortion is	APPROVED	26/08/2011
Wile pristorie		not available.	,	20,00,2011
		Termination of pregnancy where medical abortion is assessed clinically as the		
Mifepristone		most appropriate method for the woman, including when surgical abortion is	APPROVED	26/08/2011
		not available.		_5,55,_55_
		Termination of pregnancy where medical abortion is assessed clinically as the		
Mifepristone		most appropriate method for the woman, including when surgical abortion is	APPROVED	26/08/2011
·		not available.		
		Termination of pregnancy where medical abortion is assessed clinically as the		
Mifepristone		most appropriate method for the woman, including when surgical abortion is	APPROVED	26/08/2011
•		not available.		
Multiple Allergen Skin Test	ALK-Abello		ADDDOVED	12/02/2012
Reagents (ALK-Abello)	ALK-ADEIIO	for skin prick testing for allergies	APPROVED	12/02/2013
Mifepristone		for medical abortion in first trimester	APPROVED	9/11/2011
Mifepristone		for medical abortion in first trimester	APPROVED	9/11/2011
Mifepristone		for medical abortion in first trimester	APPROVED	9/11/2011
Mifepristone		for medical abortion in first trimester	APPROVED	9/11/2011
Mifepristone		for medical abortion in first trimester	APPROVED	9/11/2011
Mifepristone		for medical abortion in first trimester	APPROVED	9/11/2011
		Termination of pregnancy where medical abortion is assessed clinically as the		
Mifepristone		most appropriate method for the woman, including when surgical abortion is	APPROVED	9/11/2011
		not available.		
		Termination of pregnancy where medical abortion is assessed clinically as the		
Mifepristone		most appropriate method for the woman, including when surgical abortion is	APPROVED	9/11/2011
		not available.		
		Termination of pregnancy where medical abortion is assessed clinically as the		
Mifepristone		most appropriate method for the woman, including when surgical abortion is	APPROVED	9/11/2011
		not available.		
		Termination of pregnancy where medical abortion is assessed clinically as the		
Mifepristone		most appropriate method for the woman, including when surgical abortion is	APPROVED	9/11/2011
		not available.		
		Termination of pregnancy where medical abortion is assessed clinically as the		- 4 4
Mifepristone		most appropriate method for the woman, including when surgical abortion is	APPROVED	9/11/2011
		not available.		
Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health	APPROVED	11/05/2012
•		policy directives and RWH guidelines.		• •
Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health	APPROVED	11/05/2012
•		policy directives and RWH guidelines.		· ·
Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health	APPROVED	11/05/2012
·		policy directives and RWH guidelines.		•

Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health policy directives and RWH guidelines.	APPROVED	11/05/2012
Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health policy directives and RWH guidelines.	APPROVED	11/05/2012
Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health policy directives and RWH guidelines.	APPROVED	11/05/2012
Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health policy directives and RWH guidelines.	APPROVED	11/05/2012
Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health policy directives and RWH guidelines.	APPROVED	11/05/2012
Mifepristone		for medical abortion in first trimester	APPROVED	3/02/2012
cholecystokinin	Kinevac/ Sincalide	for assessment of gall bladder function in patients with suspected chronic acalculous cholecystitis	APPROVED	8/11/2011
cholecalciferol 1.25mg (50,000iu)		for the treatment of moderate to severe Vitamin D deficiency	APPROVED	27/10/2011
cholecalciferol 1.25mg (50,000iu)		for the treatment of moderate to severe Vitamin D deficiency	APPROVED	27/10/2011
cholecalciferol 1.25mg (50,000iu)	Cal D forte	for the treatment of moderate to severe vitamin D deficiency	APPROVED	27/10/2011
Multiple Allergen Skin Test Reagents (Greer Laboratories U.S.A)		Allergy skin test reagents are to be used in patients to assist in the diagnosis of life threatening allergic reactions	APPROVED	24/01/2012
cholecalciferol 1.25mg (50,000iu)		for the treatment of moderate to severe Vitamin D deficiency	APPROVED	7/11/2011
cholecalciferol 50,000 iu	Cal. D. Forte	for treatment of moderate to severe Vitamin D deficiency	APPROVED	7/11/2011
cholecalciferol 50,000 iu	Cal. D. Forte	for treatment of moderate to severe Vitamin D deficiency	APPROVED	7/11/2011
Cholecalciferol 100,000 units i.m. injection	D3- Vicotrat	for treatment of vitamin D deficiency and malabsorption	APPROVED	28/02/2012
Dydrogesterone (Duphaston) 10mg tablets	Duphaston	for short term treatment of oestrogen deficiency symptoms in women with an intact uterus	APPROVED	6/08/2012
Multiple Allergen Skin Test Reagents (Stallergenes/Alvostal)		for skin prick testing for allergy assessment	APPROVED	31/07/2012
Multiple Allergen Skin Test Reagents (Hollister-Stierl)		for skin prick testing for allergy assessment	APPROVED	31/07/2012
cholecalciferol		for treatment of moderate to severe Vitamin D deficiency	APPROVED	20/07/2012
cholecalciferol		for treatment of moderate to severe Vitamin D deficiency	APPROVED	20/07/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	20/07/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	for treatment of preterm who have a gestational age at birth of less than 32 weeks or birth weight less than 1500 grams and on enteral feed for at least 48 hours for prevention of necrotising enterocolitis (NEC)	APPROVED	24/07/2012
Cantharone	Cantharidin	warts molluscum contagiosum	APPROVED	29/11/2011
Celiprolol Hydrochloride 200mg Tablets		Vascular Ehlers Danlos (EDS)	APPROVED	10/01/2012

Celiprolol Hydrochloride 200mg Tablets		Vascular Ehlers Danlos (EDS)	APPROVED	10/01/2012
Celiprolol Hydrochloride 200mg Tablets		Vascular Ehlers Danlos (EDS)	APPROVED	10/01/2012
Indocyanine Green		during retinal angiography	APPROVED	28/11/2011
Moorefields Phenylephrine				
0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	29/11/2011
Lorazepam Injections		acute arousal and agitation in patients with psychosis	APPROVED	29/11/2011
oyrazinamide		treatment of tuberculosis	APPROVED	28/11/2011
Multiple Allergen Skin Test Reagents		skin prick testing for allergies to inhaled and ingested allergens	APPROVED	6/02/2012
Mifepristone		Midtrimester termination of pregnancy	APPROVED	11/05/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	30/03/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)		for skin prick testing for allergy testing.	APPROVED	20/03/2012
cholecalciferol 1.25mg (50,000IU)	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	18/12/2012
cholecalciferol 1.25mg (50,000	Cal D Forte, D-3-50	moderate to severe vitamin D deficiency	APPROVED	18/12/2012
cholecalciferol 1.25mg (50,000	Cal D Forte, D-3-50	moderate to severe vitamin D deficiency	APPROVED	18/12/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	19/12/2012
Mifepristone		Medical abortion in 1st and 2nd trimester (foetal abnormalities, serious/life threatening condition)Cervical Priming prior to surgical abortion in the 1st and 2nd trimesters	APPROVED	21/12/2012
Mifepristone		Medical abortion in 1st and 2nd trimester (foetal abnormalities, serious/life threatening condition)Cervical Priming prior to surgical abortion in the 1st and 2nd trimesters	APPROVED	21/12/2012
Mifepristone		for medical abortion in first trimester (up to 63 days), medical abortion in 2nd trimester, cervical priming prior to surgical abortion (12-15 weeks gestation)	APPROVED	23/05/2012
Cyclopentolate 0.2% Phenylephrine 1%	Cyclomydril	pupil dilation	APPROVED	30/05/2012
Mifepristone		for medical abortion in first trimester (up to 63 days)	APPROVED	11/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
holecalciferol		vitamin D deficiency	APPROVED	7/11/2011
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	29/06/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	29/06/2012
DAP-kit [penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)]	penicilloyl-poly-L-lysine (PPL) and minor determinant mixture	for skin prick and intradermal allergy testing for investigation of beta- lactam/penicillin	APPROVED	23/05/2012

Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	8/11/2011
Mifepristone		for medical abortion in first trimester	APPROVED	3/09/2012
Cyclosporin Eye Drops	Restasis	Severe inflammatory external eye disease causing dry eye,	APPROVED	20/04/2012
Methacholine		asthma challenge (bronchoprovocation) testing	APPROVED	20/04/2012
Multiple Allergens (full range)	Alyostal Skin testing reagents	skin prick testing for allergies	APPROVED	23/05/2012
DAP-kit [penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)]	penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)	for skin prick and intradermal allergy testing for investigation of beta- lactam/penicillin	APPROVED	23/05/2012
DAP-kit [penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)]	penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)	for skin prick and intradermal allergy testing for investigation of beta- lactam/penicillin	APPROVED	23/05/2012
cholecalciferol	(IVIDIVI)	moderate to severe Vitamin D deficiency	APPROVED	3/08/2011
Fosfomycin tromethamine		for treatment of lower urinary tract infections cuased by multi-drug resistant gram negative organisms (ESBL)	APPROVED	6/06/2012
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Indocyanine Green		for use during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	18/07/2011
Penicillin Allergenic Determinants (PAD)		Diagnosis of penicillin allergic readtions	APPROVED	18/07/2011
Triamcinolone Hexacetonide		for intra-articular injection in children with inflammatory arthritis	APPROVED	6/09/2011
Multiple Allergen Skin Test Reagents (Alyostal)		Allergy Testing - skin prick test	APPROVED	18/07/2011
ALK-Abello Skin Prick Testing Reagents		Allergy Testing - skin prick test	APPROVED	18/07/2011
Diater DA Skin Prick Testing Reagents		Allergy Testing - skin prick test	APPROVED	18/07/2011
Multiple Allergen Skin Test Reagents	Alyostal	for skin prick testing for allergies	APPROVED	19/07/2011
ALK-Abello Skin Prick Testing Reagents		Skin prick testing for diagnostic allergy testing	APPROVED	19/07/2011
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing in allergy testing	APPROVED	19/07/2011
ALK-Abello Skin prick testing reagents		for skin prick testing in allergy testing	APPROVED	19/07/2011
Pipothiazine palmitate (Piportil) depot injection	Piportil	treatment of psychosis when the patient has intolerable side effect to other depot injections	APPROVED	8/08/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	19/07/2011

ALK-Albello Skin prick testing reagents		for skin prick testing for allergies	APPROVED	19/07/2011
Alyostal skin prick testing reagents (Stallergenes)		Allergy Testing - skin prick test	APPROVED	19/07/2011
ALK-Abello Skin prick testing reagents		Allergy Testing - skin prick test	APPROVED	19/07/2011
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	19/07/2011
ALK-ABELLO Skin prick testing reagents		Allergy Testing - skin prick test	APPROVED	19/07/2011
Multiple Allergen Skin Test Reagents	Alyostal	for skin prick testing for allergies	APPROVED	19/07/2011
ALK-Abello Skin prick testing reagents		Allergy Testing - skin prick test	APPROVED	19/07/2011
Multiple Allergen Skin Test Reagents	Alyostal	for skin prick testing for allergies	APPROVED	19/07/2011
ALK-Abello Skin prick testing reagents		for skin prick testing for allergies	APPROVED	19/07/2011
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011

	For the management of pregnancy loss and medical termination of pregnancy skin prick testing for for allergies skin prick testing for allergies for medical abortion in first trimester	APPROVED	8/07/2011 18/07/2011 18/07/2011 28/07/2011 28/07/2011 28/07/2011 28/07/2011 28/07/2011
	skin prick testing for allergies for medical abortion in first trimester	APPROVED APPROVED APPROVED APPROVED APPROVED APPROVED APPROVED APPROVED	18/07/2011 28/07/2011 28/07/2011 28/07/2011 28/07/2011 28/07/2011 28/07/2011
	skin prick testing for allergies for medical abortion in first trimester	APPROVED APPROVED APPROVED APPROVED APPROVED APPROVED APPROVED APPROVED	18/07/2011 28/07/2011 28/07/2011 28/07/2011 28/07/2011 28/07/2011 28/07/2011
	for medical abortion in first trimester	APPROVED APPROVED APPROVED APPROVED APPROVED APPROVED	28/07/2011 28/07/2011 28/07/2011 28/07/2011 28/07/2011 28/07/2011
	for medical abortion in first trimester	APPROVED APPROVED APPROVED APPROVED APPROVED APPROVED	28/07/2013 28/07/2013 28/07/2013 28/07/2013 28/07/2013 28/07/2013
	for medical abortion in first trimester	APPROVED APPROVED APPROVED APPROVED APPROVED	28/07/2013 28/07/2013 28/07/2013 28/07/2013 28/07/2013
	for medical abortion in first trimester	APPROVED APPROVED APPROVED	28/07/2013 28/07/2013 28/07/2013 28/07/2013
	for medical abortion in first trimester	APPROVED APPROVED APPROVED	28/07/2013 28/07/2013 28/07/2013
	for medical abortion in first trimester for medical abortion in first trimester for medical abortion in first trimester	APPROVED APPROVED	28/07/2011 28/07/2011
	for medical abortion in first trimester for medical abortion in first trimester	APPROVED	28/07/2013
	for medical abortion in first trimester		28/07/2013
		APPROVED	
	for medical abortion in first trimester		28/07/2013
		APPROVED	28/07/201
	for therapeutic and diagnostic use	APPROVED	8/07/201
	Allergy Testing - skin prick test	APPROVED	19/07/201
	skin prick testing for allergies	APPROVED	12/08/201
in ava a / Cin aalida	una in mualagu maadisina hiliamustuudiaa	ADDDOVED	15/00/2016
,			15/08/2013
inevac/ Sincalide			25/08/2013
		APPROVED	15/08/2013
		APPROVED	15/08/2011
LK Abello USA Skin esting Reagents	Skin prick testing for allergies	APPROVED	15/08/2011
lyostal - Stallergenes	Skin prick testing for allergies	APPROVED	15/08/2013
LK-Abello	for therapeutic and diagnostic management of allergic disease	APPROVED	15/08/2013
LK-Abello	for therapeutic and diagnostic management of allergic disease	APPROVED	15/08/201
	for skin prick testing for allergies	APPROVED	25/08/201
nfloran	pretern neonates born 32 weeks of gestation, for prevention of necrotising	APPROVED	27/09/201
nfloran	pretern neonates born 32 weeks of gestation, for prevention of necrotising	APPROVED	27/09/201
nfloran	pretern neonates born 32 weeks of gestation, for prevention of necrotising	APPROVED	27/09/201
			30/09/201
ir e lly	esting Reagents yostal - Stallergenes .K-Abello .K-Abello floran	Allergy Testing - skin prick test skin prick testing for allergies use in nuclear medicine biliary studies for use in nuclear medicine biliary studies ophthalmic angiography during vitreo-retinal suegery and for intravenous injection to perform ICG angiography Skin prick testing for allergies A.K-Abello for therapeutic and diagnostic management of allergic disease for skin prick testing for allergies for skin prick testing for allergies pretern neonates born 32 weeks of gestation, for prevention of necrotising enterocolitis (NEC) and mortality pretern neonates born 32 weeks of gestation for prevention of necrotising enterocolitis (NEC) and mortality pretern neonates born 32 weeks of gestation for prevention of necrotising enterocolitis (NEC) and mortality pretern neonates born 32 weeks of gestation for prevention of necrotising enterocolitis (NEC) and mortality pretern neonates born 32 weeks of gestation for prevention of necrotising enterocolitis (NEC) and mortality	Allergy Testing - skin prick test skin prick testing for allergies APPROVED skin prick testing for allergies nevac/ Sincalide use in nuclear medicine biliary studies ophthalmic angiography during vitreo-retinal suegery and for intravenous injection to perform ICG angiography Skin prick testing for allergies APPROVED APPROVED APPROVED APPROVED Skin prick testing for allergies APPROVED for skin prick testing for allergies APPROVED floran pretern neonates born 32 weeks of gestation, for prevention of necrotising enterocolitis (NEC) and mortality pretern neonates born 32 weeks of gestation, for prevention of necrotising enterocolitis (NEC) and mortality pretern neonates born 32 weeks of gestation, for prevention of necrotising enterocolitis (NEC) and mortality pretern neonates born 32 weeks of gestation, for prevention of necrotising enterocolitis (NEC) and mortality APPROVED

Multiple Allergen Skin Prick Test Reagents	ALK-Abello	For skin prick testing for diagnostic allegy testing	APPROVED	23/09/2011
Multiple Allergen Skin Prick Test	Alyostal	For skin prick testing for diagnostic allegy testing	APPROVED	23/09/2011
Reagents				
DAP-kit [penicilloyl-poly-L (PPL)		for penicillin allergy skin prick testing	APPROVED	23/09/2011
and minor determinant mixture (MDM)]		for perilclini anergy skin prick testing	APPROVED	23/09/2011
Multiple AllergenSkin Test	ALK Abello Skin Prick	skin prick testing for allergies	APPROVED	27/07/2011
Reagents (ALK-Abello)	Testing reagents	skill prick testing for allergies	AFFROVED	27/07/2011
Human Serum Albumin with	Human Serum Albumin	for therapeutic and diagnostic use	APPROVED	27/07/2011
Phenol Diluent	with Phenol	tor therapeutic and diagnostic use	APPROVED	27/07/2011
Normal Saline with Phenol Diluent	ALK-Abello	for therapeutic and diagnostic use	APPROVED	27/07/2011
cholecystekinin	Kinevac/ Sincalide	use in nuclear medicine biliary studies	APPROVED	25/08/2011
Multiple Allergen Skin Test		·		
Reagents (ALK-Abello)		for skin prick testing for diagnostic allergy testing.	APPROVED	25/08/2011
DAP-kit [penicilloyl-poly-L (PPL)				
and minor determinant mixture		to confirm or refute penicillin allergy in patients who require penicillin therapy	APPROVED	25/08/2011
[MDM)]				, ,
Normal Saline with Phenol				
Diluent		For therapeutic and diagnostic management of allergic disease.	APPROVED	25/08/2011
Human Serum Albumin with				
Phenol Diluent	ALK-Abello	For therapeutic and diagnostic management of allergic disease.	APPROVED	25/08/2011
Multiple Allergen Skin Test				
Reagents (Alyostal)		skin prick testing for allergies	APPROVED	13/09/2011
Multiple Allergen Skin Test				
Reagents(ALK-Abello)		skin prick testing for diagnostic allergy testing	APPROVED	13/09/2011
DAP-kit [penicilloyl-poly-L (PPL)				
and minor determinant mixture		skin prick testing for diagnostic allergy testing	APPROVED	25/08/2011
MDM)]		, , , , , , , , , , , , , , , , , , ,		-,, -
ndocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography.	APPROVED	22/11/2011
cholecystokinin	Sincalide, Kinevac	for imaging of the biliary tract	APPROVED	25/08/2011
cholecystekinin	Kinevac/ Sincalide	use in nuclear medicine biliary studies	APPROVED	25/08/2011
Cholecystokinin	Sincalide, Kinevac	for imaging of the biliary tract	APPROVED	12/09/2011
cholecalciferol 1.25mg	Cal D forte	for the treatment of moderate to severe vitamin D deficiency	APPROVED	12/09/2011
cholecalciferol 1.25mg	Cal D forte	for the treatment of moderate to severe vitamin D deficiency	APPROVED	12/09/2011
cholecalciferol 1.25mg	Cal D forte	for the treatment of moderate to severe vitamin D deficiency	APPROVED	12/09/2011
cholecalciferol 1.25mg	Cal D forte	for the treatment of moderate to severe vitamin D deficiency	APPROVED	12/09/2011
cholecalciferol 1.25mg	Cal D forte	for the treatment of moderate to severe vitamin D deficiency	APPROVED	12/09/2011
Shorecarcher 1.23mg	Cui D TOTIC	Termination of pregnancy where medical abortion is assessed clinically as the	ATTROVED	12,03,2011
Mifepristone		most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011

Sodium Benzoate		in patients with: urea cycle disorders, nonketotic hyperglycinaemia and acute neonatal hyperammonaemia due to other metabolic disorders (including organic acidurias, methylmalonic acidaemia and propionic acidaemia)	APPROVED	6/09/2011
Cholecystokinin	Sincalide (Kinevac)	for assessment of gall bladder function in patients with suspected chronic acalculous cholecystitis	APPROVED	23/09/2011
DAP-Kit [penicilloyl-poly-l-lysine (PPL) and minor determinant mixture (MDM)]	Diater DAP-Kit	for penicillin allergy testing	APPROVED	23/09/2011
cholecalciferol 1.25mg	Cal. D. Forte	for treatment of moderate to severe Vitamin D deficiency	APPROVED	25/08/2011
Metolazone 5mg	Zaroxolyn/Diulo	the treatment of oedema or fluid retention unresponsive to other diuretics in patients with heart failure	APPROVED	6/09/2011
Multiple Food Allergens	Alyostal	for diagnostic purposes in patients who require skin prick allergy tests	APPROVED	23/09/2011
cholecystekinin		for nuclear medicine biliary studies	APPROVED	23/09/2011
sodium Benzoate (intravenous njection 2 g/10 mL and oral ablets 500 mg)		for treatment of urea cycle disorders	APPROVED	6/09/2011
Sodium Benzoate (intravenous injection 2 g/10 mL and oral tablets 500 mg)		for treatment of urea cycle disorders	APPROVED	6/09/2011
Sodium Benzoate (intravenous injection 2 g/10 mL and oral tablets 500 mg)		for treatment of urea cycle disorders	APPROVED	6/09/2011
Sodium Benzoate (intravenous njection 2 g/10 mL and oral tablets 500 mg)		for treatment of urea cycle disorders	APPROVED	6/09/2011
Sodium Benzoate (intravenous njection 2 g/10 mL and oral cablets 500 mg)		for treatment of urea cycle disorders	APPROVED	6/09/2011
cholecystekinin	Kinevac/ Sincalide	for use in nuclear medicine biliary studies	APPROVED	23/09/2011
Corticotrophin Releasing Hormone (CRH)		diagnosis of Cushing's Syndrome	APPROVED	6/09/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011

Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	21/09/2011
Human Serum Albumin with Phenol Diluent	ALK-Abello	for therapeutic and diagnostic management of allergic disease	APPROVED	21/09/2011
Normal Saline with Phenol Diluent	ALK-Abello	for therapeutic and diagnostic management of allergic disease	APPROVED	21/09/2011
Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	for skin prick testing for allergies	APPROVED	21/09/2011
DAP-Kit [penicilloyl-poly-l-lysine (PPL) and minor determinant mixture (MDM)]	Diater DAP-Kit	for penicillin allergy testing	APPROVED	21/09/2011
Flammacerium	silversulfadiazine 10mg/g, 22mg/g cerium nitrate	for wound management of full thickness burns	APPROVED	23/09/2011
DAP-Kit [penicilloyl-poly-l-lysine (PPL) and minor determinant mixture (MDM)]	Diater DAP-Kit	for penicillin allergy testing	APPROVED	23/09/2011
Multiple Allergen Skin Test Reagents(Alyostal)		for skin prick testing for allergies	APPROVED	23/09/2011
Lutetium-177 Octreotate		for the treatment of metastatic neuroendocrine tumours	APPROVED	23/09/2011
Lutetium-177 Octreotate		for the treatment of metastatic neuroendocrine tumours	APPROVED	23/09/2011
Lutetium-177 Octreotate		for the treatment of metastatic neuroendocrine tumours	APPROVED	23/09/2011
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	13/09/2011
Triamcinolone Hexacetonide		for intra-articular injection in children with inflammatory arthritis	APPROVED	6/09/2011
Mifepristone		To improve the outcome of therapeutic termination of Pregnancy	APPROVED	17/02/2012
Mifepristone		To improve the outcome of therapeutic termination of Pregnancy	APPROVED	17/02/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	23/09/2011
Multiple Allergen Skin Test Reagents (ALK-Abello)		for skin prick testing for allergies	APPROVED	23/09/2011
Human Serum Albumin with Phenol Diluent		for therapeutic and diagnostic management of allergic disease	APPROVED	23/09/2011
Normal Saline with Phenol Diluent		for therapeutic and diagnostic management of allergic disease	APPROVED	23/09/2011
DAP-Kit [penicilloyl-poly-l-lysine (PPL) and minor determinant mixture (MDM)]		for penicillin allergy testing	APPROVED	23/09/2011
Methacholine		to assess airway bronchial hyperesponsiveness	APPROVED	12/09/2011
Methacholine		to assess airway bronchial hyperesponsiveness	APPROVED	12/09/2011
cholecalciferol 1.25mg	Cal. D. Forte	for treatment of moderate to severe Vitamin D deficiency	APPROVED	6/09/2011
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergy testing.	APPROVED	23/09/2011

Multiple Allergen Skin Test Reagents (ALK-Abello)		for skin prick testing for allergy testing.	APPROVED	23/09/2011
Human Serum Albumin with				
Phenol Diluent	ALK-Abello	For therapeutic and diagnostic management of allergic disease.	APPROVED	9/11/2011
Normal Saline with Phenol	ALK-Abello	For therapeutic and diagnostic management of allergic disease.	APPROVED	9/11/2011
Diluent	ALK-ABEIIO	To the apeutic and diagnostic management of allergic disease.	ATTROVED	3/11/2011
DAP-Kit [penicilloyl-poly-l-lysine				
(PPL) and minor determinant	Diater DAP-Kit	for penicillin allergy testing	APPROVED	23/09/2011
mixture (MDM)]				
Mifepristone		for medical termination of an intra-uterine pregnanacy up to 63 days	APPROVED	10/01/2012
Mifepristone		for medical termination of an intra-uterine pregnanacy up to 63 days	APPROVED	10/01/2012
Mifepristone		for medical termination of an intra-uterine pregnanacy up to 63 days	APPROVED	10/01/2012
Mifepristone		for medical termination of an intra-uterine pregnanacy up to 63 days	APPROVED	10/01/2012
cholecystokinin	sincalide	for imaging of the biliary tract	APPROVED	23/09/2011
cholecystokinin		for imaging of the biliary tract	APPROVED	23/09/2011
cholecalciferol		for moderate to severe Vitamin D deficiency	APPROVED	27/09/2011
		for treatment of nausea and vomitting, delirium and terminal agittion in		
Levomepromazine		palliative care patients	APPROVED	22/09/2011
		for treatment of nausea and vomitting, delirium and terminal agittion in	400001/50	22/00/2044
Levomepromazine		palliative care patients	APPROVED	22/09/2011
ndocyanine Green		diagnosis of retinal pathologies	APPROVED	8/11/2011
cholecystekinin		to facilitate investigation of gall bladder function	APPROVED	14/11/2011
Human Serum Albumin with Phenol Diluent	ALK-Abello Human Serum Albumin with Phenol Diluent	for therapeutic and diagnostic use	APPROVED	9/11/2011
Normal Saline with Phenol Diluent	ALK-Abello Normal Saline with Phenol Diluent	for therapeutic and diagnostic use	APPROVED	9/11/2011
Multiple Allergen Skin Test Reagents (Alyostal)	Alyostal	for skin prick allergy testing	APPROVED	9/11/2011
DAP-Kit [penicilloyl-poly-l-lysine (PPL) and minor determinant mixture (MDM)]	Diater DAP-Kit	for penicillin allergy testing	APPROVED	9/11/2011
Multiple Allergen Skin Test Reagents (ALK-Abello)	Alk-Abello	for skin prick testing for allergies	APPROVED	9/11/2011
ndocyanine Green		visualisation of blod vessels during neurosurgery	APPROVED	14/11/2011
Multiple Allergen Skin Test				
Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	14/09/2012
ndocyanine Green		visualisation of blod vessels during neurosurgery	APPROVED	14/11/2011
ndocyanine Green		visualisation of blod vessels during neurosurgery	APPROVED	14/11/2011
cholecalciferol		vitamin D deficiency	APPROVED	7/11/2011
cholecalciferol		vitamin D deficiency	APPROVED	7/11/2011
cholecalciferol		vitamin D deficiency	APPROVED	7/11/2011
cholecalciferol		vitamin D deficiency	APPROVED	15/11/2011

cholecalciferol 1.25mg		moderate to severe Vitamin D deficiency	APPROVED	15/11/2011
cholecalciferol 1.25mg		moderate to severe Vitamin D deficiency	APPROVED	7/11/2011
riamcinolone hexacetonide	Aristospan	Intra-articular injection for treatment purposes in patients with inflammatory arthritis in Juvenile Idiopathic Arthritis (JIA)	APPROVED	24/10/2011
ALK-Abello skin prick testing reagents for allergy testing		management of allergic disease	APPROVED	9/11/2011
Destradiol Implant	Estrapel Implant 50mg	Management of oestrogen deficiency symptoms due to natural or surgical menopause	APPROVED	14/10/2011
cholecalciferol 50,000 iu	Cal. D. Forte	for treatment of moderate to severe Vitamin D deficiency	APPROVED	7/11/2011
Mifepristone		Severe maternal medical disease contraindicating the continuation of preganancy in 1st & 2nd trimester of pregnancy. Foetal abnormality in 1st & 2nd trimester, intrauterine fetal demise in 1st & 2nd trimester	APPROVED	9/11/2011
DAP-kit [penicilloyl-poly-L (PPL) and minor determinant mixture MDM)]		for skin prick testing for diagnosis of penicillin allergy	APPROVED	14/11/2011
ndocyanine green		for intravenous injection to perform ICG angiography	APPROVED	14/11/2011
Diater DAP-kit (penicilloyl-poly-		1.5		1.,11,2011
. (PPL) and minor determinant mixture (MDM)		intradermal skin prick and desensitization procedures	APPROVED	14/11/2011
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	2/12/2011
Multiple Allergen Skin Test Reagents	ALK-Abello	to diagnose allergic triggers in patients	APPROVED	14/11/2011
Multiple Allergen Skin Test Reagents	Alyostal	for skin testing allergic diseases	APPROVED	14/11/2011
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	17/11/2011
Mifepristone		for medical termination of an intra-uterine pregnanacy up to 63 days	APPROVED	16/01/2012
pyrazinamide		for the treatment of tuberculosis	APPROVED	22/11/2011
oyrazinamide		for the treatment of tuberculosis	APPROVED	22/11/2011
oyrazinamide		for the treatment of tuberculosis	APPROVED	22/11/2011
oyrazinamide		for the treatment of tuberculosis	APPROVED	22/11/2011
pyrazinamide		for the treatment of tuberculosis	APPROVED	22/11/2011
pyrazinamide		for the treatment of tuberculosis	APPROVED	22/11/2011
Mifepristone		Medical abortion to 63 days gestation. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	16/01/2012
riamcinolone hexacetonide		Intra-articular injection for treatment purposes in patients with inflammatory arthritis in Juvenile Idiopathic Arthritis (JIA)	APPROVED	22/11/2011
Cholecalciferol 1.25mg 50,000iu)	Cal D Forte	moderate to severe Vitamin D deficiency	APPROVED	27/01/2012
ndocyanine Green		evaluation of liver function	APPROVED	6/12/2011
Cholecystokinin	sincalide	for imaging of the biliary tract.	APPROVED	6/12/2011
DAP-Kit [penicilloyl-poly-l-lysine PPL) and minor determinant	Diater DAP-Kit	for penicillin allergy testing	APPROVED	15/12/2011

Diater DAP skin prick testing reagents		Penicillian allergy testing	APPROVED	15/12/2011
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	14/12/2011
ndocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	10/01/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	10/01/2012
Mifepristone		termnation of pregnancy up to 49 days gestation	APPROVED	28/02/2012
Primacin Tablets 7.5mg (primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria		15/12/2011
Primacin Tablets 7.5mg (primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria		15/12/2011
Primacin Tablets 7.5mg (primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria		15/12/2011
Primacin Tablets 7.5mg (primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria		15/12/2011
Primacin Tablets 7.5mg (primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria		15/12/2011
Primacin Tablets 7.5mg (primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria		15/12/2011
Primacin Tablets 7.5mg primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria		15/12/2011
Primacin Tablets 7.5mg primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria		15/12/2011
Estrapel Oestradiol Implants		management of oestrogen deficiency symptoms due to natural or surgical menopause	APPROVED	2/03/2012
Cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	27/01/2012
Multiple Allegen Skin Test Reagents (Alyostal)		for skin prick testing for allergic disease	APPROVED	24/01/2012
Pirfenidone		Idiopathic Pulmonary Fibrosis	APPROVED	26/03/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	13/01/2012
DAP-Kit [penicilloyl-poly-l-lysine (PPL) and minor determinant mixture (MDM)]	Diater DAP-Kit	for penicillin allergy testing	APPROVED	6/02/2012
Triamcinolone Acetonide		Macular Oedema	APPROVED	16/01/2012

Triamcinolone Acetonide	Macular Oedema	APPROVED	16/01/2012
Triamcinolone Acetonide	Macular Oedema	APPROVED	16/01/2012
Triamcinolone Acetonide	Macular Oedema	APPROVED	16/01/2012
Triamcinolone Acetonide	Macular Oedema	APPROVED	16/01/2012
Triamcinolone Acetonide	Macular Oedema	APPROVED	16/01/2012
Triamcinolone Acetonide	Macular Oedema	APPROVED	16/01/2012
Multiple Allergen Skin Test			
Reagents (ALK-Abello)	Allergy Testing - skin prick test	APPROVED	6/02/2012
Diater DAP Skin Prick Testing			0/00/00/0
Reagents	Allergy Testing - skin prick test	APPROVED	6/02/2012
Dihydroergotamine	orthostatic hypotension due to autonomic failure or post-prandial hypotension and syncope	APPROVED	20/01/2012
	orthostatic hypotension due to automatic failure or post-prandial hypotension		
Dihydroergotamine	and syncope	APPROVED	20/01/2012
	orthostatic hypotension due to automatic failure or post-prandial hypotension		
Dihydroergotamine	and syncope	APPROVED	20/01/2012
	recurrent normal or low blood pressure vasovagal syncope, postural orthostatic		
Midodrine	tachycardia syndrome, orthostatic hypotension due to autonomic failure or	APPROVED	20/01/2012
Wildouthic	post-prandial hypotension and syncope	AITROVED	20/01/2012
	recurrent normal or low blood pressure vasovagal syncope, postural orthostatic		
Midodrine	tachycardia syndrome, orthostatic hypotension due to autonomic failure or	APPROVED	20/01/2012
wiidodi iiie	post-prandial hypotension and syncope	ALLINOVED	20/01/2012
	recurrent normal or low blood pressure vasovagal syncope, postural orthostatic		
Midodrine	tachycardia syndrome, orthostatic hypotension due to autonomic failure or	APPROVED	20/01/2012
wiidodi iiie	post-prandial hypotension and syncope	ALLINOVED	20/01/2012
Multiple Allergen Skin Test	post-prantital hypotension and syncope		
-	for skin prick testing for allergies	APPROVED	27/02/2012
Reagents (ALK-Abello) Multiple Allergen Skin Test			
-	for skin prick testing for allergies	APPROVED	27/02/2012
Reagents (Alyostal) Mifepristone	Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone	Termination of pregnancies in mid-trimester pregnancies Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone	Termination of pregnancies in mid-trimester pregnancies Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone	Termination of pregnancies in mid-trimester pregnancies Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
		APPROVED	17/02/2012
Mifepristone Mifepristone	Termination of pregnancies in mid-trimester pregnancies Termination of pregnancies in mid-trimester pregnancies		
Mifepristone Mifepristone		APPROVED APPROVED	17/02/2012 17/02/2012
Mifepristone Mifepristone	Termination of pregnancies in mid-trimester pregnancies	APPROVED	
Mifepristone Mifepristone	Termination of pregnancies in mid-trimester pregnancies		17/02/2012
Mifepristone	Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone	Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone	Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone	Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone	Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone	Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone	Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012

Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Multiple Allergen Skin Test		for skin prick testing for allergies	APPROVED	27/02/2012
Reagents (Alyostal)		for skill prick testing for allergies	APPROVED	27/02/2012
Cholecalciferol 1.25mg	Cal D Forte	moderate to severe Vitamin D deficiency	APPROVED	27/01/2012
(50,000iu)	Cai D Forte	moderate to severe vitamin b denciency	APPROVED	27/01/2012
Cholecalciferol 1.25mg	Cal D Forte	moderate to severe Vitamin D deficiency	APPROVED	27/01/2012
(50,000iu)	Cai D Forte	moderate to severe vitamin b denciency	APPROVED	27/01/2012
Cholecalciferol 1.25mg	Cal D Forte	moderate to severe Vitamin D deficiency	APPROVED	27/01/2012
(50,000iu)	Cai D Forte	moderate to severe vitamin b denciency	APPROVED	27/01/2012
Indocyanine Green		for intravenous injection to perform retinal angiography	APPROVED	17/08/2012
Cholecalciferol 1.25mg	Cal D Farta	moderate to severe Vitamia D deficiency	APPROVED	27/01/2012
(50,000iu)	Cal D Forte	moderate to severe Vitamin D deficiency	APPROVED	27/01/2012
Indocyanine Green		Vitreo-retinal surgery & intravenous injection to perform ICG angiography	APPROVED	6/02/2012
maocyanine dicen		vities retinal surgery & intravenous injection to perform less difgiography	AITIOVED	0/02/2012
Indocyanine Green		Vitreo-retinal surgery & intravenous injection to perform ICG angiography	APPROVED	6/02/2012
Indonumino Cucon		during vitreo-retinal surgery and for intravenous injection to perform ICG	ADDDOVED	C/02/2012
Indocyanine Green		angiography	APPROVED	6/02/2012
Diater DAP Skin Prick Testing		Danasillin and Anasynsillin alleges teating	ADDDOVED	12/02/2012
Reagents		Penecillin and Amoxycillin allergy testing	APPROVED	13/02/2012
Alyostal Skin Prick Testing		alloway tacting	ADDDOVED	6/02/2012
Reagents (Stallergenes)		allergy testing	APPROVED	6/02/2012
ALK-Abello Skin Prick Testing		all and a tacking	ADDDOVED	C /02 /2012
Reagents (Stallergenes)		allergy testing	APPROVED	6/02/2012
Miforgistana		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical	ADDDOVED	2/02/2012
Mifepristone		abortion in 1st and 2nd trimesters	APPROVED	3/02/2012
N differentiations		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical	ADDDOVED	2/02/2012
Mifepristone		abortion in 1st and 2nd trimesters	APPROVED	3/02/2012
N 4: £		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical	A DDDDOVED	2/02/2012
Mifepristone		abortion in 1st and 2nd trimesters	APPROVED	3/02/2012
N 4: £		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical	A DDDDOVED	2/02/2012
Mifepristone		abortion in 1st and 2nd trimesters	APPROVED	3/02/2012
Indocyanine Green		vitreo-retinal surgery and intravenous injection to perform ICG angiography	APPROVED	13/02/2012
Multiple Allergen Skin Test				
Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	13/02/2012
Mifepristone		for medical abortion in first trimester	APPROVED	3/02/2012

Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	3/02/2012
Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg,		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	3/02/2012
hvdrochlorothiazide 12.5mg) Cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	20/03/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	19/10/2012
cholecalciferol 1.25mg	Cal D Forte	moderate to severe Vitamin D deficiency	APPROVED	31/07/2012
cholecalciferol	car b rorte	moderate to severe Vitamin D deficiency	APPROVED	28/02/2012
methacholine		for bronchial provocation testing	APPROVED	16/02/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	28/02/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	for skin prick testing for allergies	APPROVED	28/02/2012
Patanase Nasal Spray (600ug olopatadine hydrochloride)		Allergic rhinitis/patients who have failed currently available therapies	APPROVED	29/06/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	23/02/2012
Multiple Allergen Skin Test Reagents(ALK-Abello)	ALK Abello	for skin prick testing for allergies	APPROVED	27/02/2012
Normal Saline with Phenol (ALK- Abello)		for skin prick testing for allergies	APPROVED	27/02/2012
ALK-Abello Normal Saline with Phenol (NSA) diluent		for skin prick testing for allergy testing.	APPROVED	20/03/2012
ALK-Abello Human Serum Albumin (HSA) diluent		for skin prick testing for allergy testing.	APPROVED	20/03/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	7/03/2012
cholecalciferol 50,000 iu		treatment of Vitamin D deficiency in patients with levels < 50mmol/L	APPROVED	13/09/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	9/03/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	16/03/2012
cholecalciferol 1.25mg	Cal. D. Forte	for treatment of moderate to severe Vitamin D deficiency	APPROVED	13/03/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	20/03/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)		for skin prick testing for allergies	APPROVED	20/03/2012
Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Estrapel Oestradiol Implants		management of oestrogen deficiency symptoms due to natural or surgical menopause	APPROVED	9/03/2012
Histamine Dichloride (1% in 3mL)		positvie control for skin prick testing for allergies	APPROVED	28/02/2012

Fosfomycin tromethamine		for treatment of lower urinary tract infections cuased by multi-drug resistant gram negative organisms (ESBL)	APPROVED	2/07/2012
Cholecystokinin	Kinevac/ Sincalide	for imaging of the biliary tract.	APPROVED	29/03/2012
clobetasol	·	Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus)	APPROVED	29/08/2012
clobetasol		Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus)	APPROVED	29/08/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	30/03/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	30/03/2012
Mifepristone		Medical abortion in 1st trimester up to 63 days. Medical abortion in 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	30/03/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	30/03/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	30/03/2012
Mifepristone		Medical abortion up to 63 days of preg in women suffering from life- threatening or otherwise serious illnesses or conditions where continuing the pregnancy poses greater risks to the woman's life or health than does induced abortion. *See approval letter*	APPROVED	11/05/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	30/03/2012
Multiple Allergen Skin Test Reagents(ALK-Abello)		skin prick testing for diagnostic allergy testing	APPROVED	20/04/2012
Diater DAP-kit [penicilloyl-poly- L (PPL) and minor determinant mixture (MDM)]	benzylpenicilloyl- polylysine (stallergenes Allergopen), sodium	for penicillin allergy skin prock testing	APPROVED	20/04/2012
Alyostal Multiple Allergens	Alyostal Skin Testing Reagents	Skin prick testing for allergies	APPROVED	20/04/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	pretern neonates born 32 weeks of gestation, for prevention of necrotising enterocolitis (NEC) and mortality	APPROVED	21/03/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	pretern neonates born 32 weeks of gestation, for prevention of necrotising enterocolitis (NEC) and mortality	APPROVED	21/03/2012
Mannitol	Bronchitol	treatment of bronchiectasis	APPROVED	10/04/2012
Levomepromazine		to treat nausea, vomiting, delirium agitation in palliative care terminal patients	APPROVED	27/03/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	28/03/2012
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	29/03/2012
Multiple Allergen Skin Test Reagents		skin prick testing for allergies	APPROVED	29/03/2012
Edrophonium Chloride		Myasthenia Gravis	APPROVED	5/04/2012

Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	3/04/2012
0.6% Intracameral Syringe		, , , , , , , , , , , , , , , , , , ,		-, - , -
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	3/04/2012
0.6% Intracameral Syringe				
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	30/03/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	30/03/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	30/03/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	30/03/2012
Mifepristone		for medical abortion in first trimester (up to 63 days)	APPROVED	5/04/2012
Mifepristone		for medical abortion in first trimester (up to 63 days)	APPROVED	5/04/2012
Mifepristone		for medical abortion in first trimester (up to 63 days)	APPROVED	5/04/2012
Mifepristone		for medical abortion in first trimester (up to 63 days)	APPROVED	5/04/2012
Mifepristone		for medical abortion in first trimester (up to 63 days)	APPROVED	5/04/2012
Mifepristone		for medical abortion in first trimester (up to 63 days)	APPROVED	5/04/2012
oyrazinamide		the treatment of tuberculosis	APPROVED	20/04/2012
oyrazinamide		the treatment of tuberculosis	APPROVED	20/04/2012
oyrazinamide		the treatment of tuberculosis	APPROVED	20/04/2012
oyrazinamide		the treatment of tuberculosis	APPROVED	20/04/2012
oyrazinamide		the treatment of tuberculosis	APPROVED	20/04/2012
oyrazinamide		the treatment of tuberculosis	APPROVED	20/04/2012
Friamcinolone Hexacetonide		Juvenile Idiopathic Arthritis	APPROVED	4/06/2012
Friamcinolone Hexacetonide		Juvenile Idiopathic Arthritis	APPROVED	4/06/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	12/04/2012
Multiple Allergen Skin Test				
Reagents (Alyostal)		skin prick testing for allergies	APPROVED	20/04/2012
Multiple Allergen Skin Test				/ /
Reagents (ALK-Abello)		skin prick testing for allergies	APPROVED	20/04/2012
Jrokinase		to unblock renal catheters	APPROVED	30/05/2012
cholecalciferol 1.25mg (50,000				
IU)	D-3-50, Cal-D-Forte	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
methacholine		for bronchial provocation testing as a diagnostic test for asthma	APPROVED	1/05/2012
Indocyanine Green		vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	23/05/2012
DAP-Kit [penicilloyl-poly-l-lysine				
(PPL) and minor determinant	Diater DAP-Kit	for diagnosis of immediate hypersensitivity to benzylpenicillin and related	APPROVED	30/05/2012
mixture (MDM)]	Didter Drill Title	antibiotics	,	30,03,201
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012

Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone		for medical abortion in first trimester	APPROVED	14/06/2012
Mifepristone		for medical abortion in first trimester	APPROVED	14/06/2012
Multiple Allergen Skin Test	ALIZ AL-III-	for this point to the first for the south of the south of	A DDD OVED	1/05/2012
Reagents(ALK-Abello)	ALK Abello	for skin prick testing for diagonstic allergy testing	APPROVED	1/06/2012
Diater DAP skin prick testing reagents		Penicillian AND Amoxycillin allergy testing	APPROVED	1/06/2012
Multiple Allergen Skin Test		allergy testing	APPROVED	1/06/2012
Reagents (Alyostal)				
Cholecalciferol 1.25mg		Moderate to severe Vitamin D deficiency	APPROVED	6/06/2012
Cholecalciferol 1.25mg		Moderate to severe Vitamin D deficiency	APPROVED	6/06/2012
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	4/06/2012
0.6% Intracameral Syringe				., 55, 2522
Progesterone (Utrogestan)		management of menopausal symptoms	APPROVED	4/06/2012
L00mg and 200mg			7 7 11.0 7 2 2	., 00, 2012
Oydrogesterone (Duphaston) 5-		management of oestrogen deficiency symptoms due to natural or surgical	APPROVED	4/06/2012
LOmg tablets		menopause	7111110125	4,00,2012
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	4/06/2012
0.6% Intracameral Syringe		tor ase in rioppy in a synarome in patients undergoing eataract sargery	ATTROVED	4,00,2012
Triamcinolone Acetonide		posterior segment uveitis and intraoperative identification of vitreous	APPROVED	25/09/2012
Triamcinolone Acetonide		posterior segment uveitis and intraoperative identification of vitreous	APPROVED	25/09/2012
Triamcinolone Acetonide		posterior segment uveitis and intraoperative identification of vitreous	APPROVED	25/09/2012
Triamcinolone Acetonide		posterior segment uveitis and intraoperative identification of vitreous	APPROVED	25/09/2012
5 Methoxypsoralen	Pentaderm	requiring treatment for psoriasis and vitiligo	APPROVED	5/06/2012
Multiple Allergen Test Reagents		for skin prick testing for allergy testing	APPROVED	12/06/2012
Fosfomycin		for treatment of lower urinary tract infections cuased by multi-drug resistant gram negative organisms (ESBL)	APPROVED	6/06/2012
DAP-kit [penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)]	penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)	for skin prick and intradermal allergy testing for investigation of beta- lactam/penicillin	APPROVED	6/06/2012
clobetasol	TIVIDIVI	Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus) conditions	APPROVED	29/08/2012
cholecalciferol 1ml injection	D3- Forte	Vitamin D deficiency and malbasorption	APPROVED	29/06/2012
Cyclizine		nausea and vomiting	APPROVED	29/06/2012
_evomepromazine		nausea and vomiting	APPROVED	29/06/2012
clobetasol		Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus) conditions	APPROVED	29/08/2012
pyrazinamide		treatment of Tuberculosis	APPROVED	2/07/2012

pyrazinamide	treatment of Tuberculosis	APPROVED	2/07/2012
pyrazinamide	treatment of Tuberculosis	APPROVED	2/07/2012
Progesterone (Utrogestan)	uterine protection while on Oestrogen	APPROVED	17/07/2012
100mg and 200mg	diterme protection while on oestrogen	ATTROVED	17/07/2012
Pollypill Version 1 (aspirin			
75mg, simvastatin 40mg,			
lisinopril 10mg, atenolol 50mg)	for continuation of treatment of participants in Kanyini GAP Study (Protocol		- 4 4
and Pollypill Version 2 (aspirin	X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
75mg, simvastatin 40mg,			
lisinopril 10mg,			
hydrochlorothiazida 17 5mg)			
Pollypill Version 1 (aspirin			
75mg, simvastatin 40mg,			
lisinopril 10mg, atenolol 50mg)	for continuation of treatment of participants in Kanyini GAP Study (Protocol	APPROVED	2/07/2012
and Pollypill Version 2 (aspirin	X08-0076) in accordance with study's approved inclusion and exclusion criteria	ATTROVED	2/0//201/
75mg, simvastatin 40mg,			
lisinopril 10mg,			
Pollypill Version 1 (aspirin			
75mg, simvastatin 40mg,			
lisinopril 10mg, atenolol 50mg)	for continuation of tracture at a mouticine ate in New ini CAR Study (Ruchaed		
and Pollypill Version 2 (aspirin	for continuation of treatment of participants in Kanyini GAP Study (Protocol	APPROVED	2/07/2012
75mg, simvastatin 40mg,	X08-0076) in accordance with study's approved inclusion and exclusion criteria		
lisinopril 10mg,			
hydrochlorothiazida 12 5mg\			
Pollypill Version 1 (aspirin			
75mg, simvastatin 40mg,			
lisinopril 10mg, atenolol 50mg)	for continuation of treatment of participants in Kanyini GAP Study (Protocol		- 1 1
and Pollypill Version 2 (aspirin	X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
75mg, simvastatin 40mg,			
lisinopril 10mg,			
hudrochlorothiazida 12 5mg\			
Pollypill Version 1 (aspirin			
75mg, simvastatin 40mg,			
lisinopril 10mg, atenolol 50mg)	for continuation of treatment of participants in Kanyini GAP Study (Protocol	APPROVED	2/07/2012
and Pollypill Version 2 (aspirin	X08-0076) in accordance with study's approved inclusion and exclusion criteria		2,0,,201
75mg, simvastatin 40mg,			
lisinopril 10mg,			
nudrochlorothiazida 12 5mal			

sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 3 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg)	Pollypill Version 1 (aspirin			
APPROVED 2/07/201 X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, without high state of participants in Kanyini GAP Study (Protocol Molypil Version 1 (aspirin Smg. simvastatin 40mg, sinopril 10mg, without high state of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, att	75mg, simvastatin 40mg,			
Sing, simvastatin 40mg, sinopril 10mg, withorship and the street of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) are continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076		for continuation of treatment of participants in Kanyini GAP Study (Protocol	A DDDOVED	2/07/2012
sinopril 10mg, survivatatin 40mg, sinopril 10mg, atenolol 50mg) and Polityill Version 1 (aspirin 55mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Polityill Version 2 (aspirin 55mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Polityill Version 10mg, sinopril 1		X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/0//2012
International Company of the Continuation of treatment of participants in Kanyini GAP Study (Protocol and Pollypill Version 1 (aspirin Smg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopr	75mg, simvastatin 40mg,			
collypill Version 1 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastati	lisinopril 10mg,			
Sing, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) in deposition of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopr				
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, sinopril 10				
APPROVED 2/07/201 Sing, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollybill Version 2 (aspirin 5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollybill Version 2 (aspirin 5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollybill Version 2 (aspirin 5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria approach to the study of				
Sing, simvastatin 40mg, sinopril 10mg, wideochlorabilasida 13 Employed inclusion and exclusion criteria (Sing, simvastatin 40mg, sinopril 10mg, set (Sinopril 10mg, sinopril 10mg, sinopri			APPROVED	2/07/2012
sinopril 10mg, withorbiographic side 12 5 mail of the process of t		X08-0076) in accordance with study's approved inclusion and exclusion criteria	7.1.11.0.12.5	2,07,2012
Interchalcosthiazida 12.5 Emb. (collapsil Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg)	-			
Sollypill Version 1 (aspirin Some, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) Ind Pollypill Version 2 (aspirin Some, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) Ind Pollypill Version 2 (aspirin Some, sinwastatin 40mg, sinopril 10mg,				
5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopri				
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, sinopril 1				
APPROVED 2/07/201 X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria		for continuation of treatment of narticipants in Kanvini CAD Study / Dratecal		
Sinopril 10mg, sinopr		·	APPROVED	2/07/2012
sinopril 10mg, wdoschlorathizaida 12.5ma) ollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg,		x08-0076) in accordance with study's approved inclusion and exclusion criteria		
ollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, simvastatin 40mg, sinopril 10mg, si	-			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, wateroble of the simple of the	hydrochlorothiazida 12 5mg)			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria APPROVED 2/07/201	Pollypill Version 1 (aspirin			
nd Pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria APPROVED 2/07/201	75mg, simvastatin 40mg,			
APPROVED 2/07/201 Some, simvastatin 40mg, sinopril 10mg, sinopril	lisinopril 10mg, atenolol 50mg)	for continuation of treatment of participants in Kanvini GAP Study (Protocol		
Some simulation 40mg, Sinopril 10mg,	and Pollypill Version 2 (aspirin		APPROVED	2/07/2012
avide chlorothiazide 12 5 mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg)	75mg, simvastatin 40mg,	7,00 0070) in decordance with study 3 approved inclusion and exclusion effective		
collypill Version 1 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, sino	lisinopril 10mg,			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 1	hydrochlorothiazida 12 5mg/			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin (Smg, simvastatin 40mg, sinopril 10mg, sinopril 10m				
APPROVED 2/07/201 X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria APPROVED 2/07/201				
X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria		for continuation of treatment of participants in Kanyini GAP Study (Protocol	A DDDOVED	2/07/2012
sinopril 10mg, sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria		X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Approximation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, Sinopril 10mg, atenology (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg,	75mg, simvastatin 40mg,			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, Sinopril 10mg, atenolol 50mg) APPROVED 2/07/201	lisinopril 10mg,			
5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenology of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg,	hudrochlorothiazida 12 5mg\ Pollypill Varsion 1 (aspirin			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg,				
nd Pollypill Version 2 (aspirin '5mg, simvastatin 40mg, sinopril 10mg, APPROVED 2/07/201	-			
5mg, simvastatin 40mg, sinopril 10mg,			APPROVED	2/07/2013
sinopril 10mg,		X08-0076) in accordance with study's approved inclusion and exclusion criteria	ATTROVED	2,01,2012

sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 3 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg)	Pollypill Version 1 (aspirin			
APPROVED 2/07/201 X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, without high state of participants in Kanyini GAP Study (Protocol Molypil Version 1 (aspirin Smg. simvastatin 40mg, sinopril 10mg, without high state of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, att	75mg, simvastatin 40mg,			
Sing, simvastatin 40mg, sinopril 10mg, withorship and the street of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) are continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076		for continuation of treatment of participants in Kanyini GAP Study (Protocol	A DDDOVED	2/07/2012
sinopril 10mg, survivatatin 40mg, sinopril 10mg, atenolol 50mg) and Polityill Version 1 (aspirin 55mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Polityill Version 2 (aspirin 55mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Polityill Version 10mg, sinopril 1		X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/0//2012
International Company of the Continuation of treatment of participants in Kanyini GAP Study (Protocol and Pollypill Version 1 (aspirin Smg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopr	75mg, simvastatin 40mg,			
collypill Version 1 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastati	lisinopril 10mg,			
Sing, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) in deposition of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopr				
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, sinopril 10				
APPROVED 2/07/201 Sing, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollybill Version 2 (aspirin 5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollybill Version 2 (aspirin 5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollybill Version 2 (aspirin 5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria approach to the study of				
Sing, simvastatin 40mg, sinopril 10mg, wideochlorabilasida 13 Employed inclusion and exclusion criteria (Sing, simvastatin 40mg, sinopril 10mg, set (Sinopril 10mg, sinopril 10mg, sinopri			APPROVED	2/07/2012
sinopril 10mg, withorbiographic side 12 5 mail of the process of t		X08-0076) in accordance with study's approved inclusion and exclusion criteria	7.1.11.0.12.5	2,07,2012
Interchalcosthiazida 12.5 Emb. (collapsil Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg)	-			
Sollypill Version 1 (aspirin Some, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) Ind Pollypill Version 2 (aspirin Some, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) Ind Pollypill Version 2 (aspirin Some, sinwastatin 40mg, sinopril 10mg,				
5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopri				
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, sinopril 1				
APPROVED 2/07/201 X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria		for continuation of treatment of narticinants in Kanvini CAD Study / Dratecol		
Sinopril 10mg, sinopr		·	APPROVED	2/07/2012
sinopril 10mg, wdoschlorathizaida 12.5ma) ollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg,		x08-0076) in accordance with study's approved inclusion and exclusion criteria		
ollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, simvastatin 40mg, sinopril 10mg, si	-			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, wateroble of the simple of the	hydrochlorothiazida 12 5mg)			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria APPROVED 2/07/201	Pollypill Version 1 (aspirin			
nd Pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria APPROVED 2/07/201	75mg, simvastatin 40mg,			
APPROVED 2/07/201 Some, simvastatin 40mg, sinopril 10mg, sinopril	lisinopril 10mg, atenolol 50mg)	for continuation of treatment of participants in Kanvini GAP Study (Protocol		
Some simulation 40mg, Sinopril 10mg,	and Pollypill Version 2 (aspirin		APPROVED	2/07/2012
avide chlorothiazide 12 5 mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg)	75mg, simvastatin 40mg,	7,00 0070) in decordance with study 3 approved inclusion and exclusion effective		
collypill Version 1 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, sino	lisinopril 10mg,			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 1	hydrochlorothiazida 12 5mg/			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin (Smg, simvastatin 40mg, sinopril 10mg, sinopril 10m				
APPROVED 2/07/201 X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria APPROVED 2/07/201				
X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria		for continuation of treatment of participants in Kanyini GAP Study (Protocol	A DDDOVED	2/07/2012
sinopril 10mg, sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria		X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Approximation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, Sinopril 10mg, atenology (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg,	75mg, simvastatin 40mg,			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, Sinopril 10mg, atenolol 50mg) APPROVED 2/07/201	lisinopril 10mg,			
5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenology of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg,	hudrochlorothiazida 12 5mg\ Pollypill Varsion 1 (aspirin			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg,				
nd Pollypill Version 2 (aspirin '5mg, simvastatin 40mg, sinopril 10mg, APPROVED 2/07/201	-			
5mg, simvastatin 40mg, sinopril 10mg,			APPROVED	2/07/2013
sinopril 10mg,		X08-0076) in accordance with study's approved inclusion and exclusion criteria	ATTROVED	2,01,2012

sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 3 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg)	Pollypill Version 1 (aspirin			
APPROVED 2/07/201 X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, without high state of participants in Kanyini GAP Study (Protocol Molypil Version 1 (aspirin Smg. simvastatin 40mg, sinopril 10mg, without high state of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, att	75mg, simvastatin 40mg,			
Sing, simvastatin 40mg, sinopril 10mg, withorship and the street of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) are continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076		for continuation of treatment of participants in Kanyini GAP Study (Protocol	A DDDOVED	2/07/2012
sinopril 10mg, survivatatin 40mg, sinopril 10mg, atenolol 50mg) and Polityill Version 1 (aspirin 55mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Polityill Version 2 (aspirin 55mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Polityill Version 10mg, sinopril 1		X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/0//2012
International Company of the Continuation of treatment of participants in Kanyini GAP Study (Protocol and Pollypill Version 1 (aspirin Smg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopr	75mg, simvastatin 40mg,			
collypill Version 1 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastati	lisinopril 10mg,			
Sing, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) in deposition of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopr				
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, sinopril 10				
APPROVED 2/07/201 Sing, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollybill Version 2 (aspirin 5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollybill Version 2 (aspirin 5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollybill Version 2 (aspirin 5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria approach to the study of				
Sing, simvastatin 40mg, sinopril 10mg, wideochlorabilasida 13 Employed inclusion and exclusion criteria (Sing, simvastatin 40mg, sinopril 10mg, set (Sinopril 10mg, sinopril 10mg, sinopri			APPROVED	2/07/2012
sinopril 10mg, withorbiographic side 12 5 mail of the process of t		X08-0076) in accordance with study's approved inclusion and exclusion criteria	7.1.11.0.12.5	2,07,2012
Interchalcosthiazida 12.5 Emb. (collapsil Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg)	-			
Sollypill Version 1 (aspirin Some, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) Ind Pollypill Version 2 (aspirin Some, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) Ind Pollypill Version 2 (aspirin Some, sinwastatin 40mg, sinopril 10mg,				
5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopri				
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, sinopril 1				
APPROVED 2/07/201 X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria		for continuation of treatment of narticinants in Kanvini CAD Study / Dratecal		
Sinopril 10mg, sinopr		·	APPROVED	2/07/2012
sinopril 10mg, wdoschlorathizaida 12.5ma) ollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg,		x08-0076) in accordance with study's approved inclusion and exclusion criteria		
ollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, simvastatin 40mg, sinopril 10mg, si	-			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, wateroble of the simple of the	hydrochlorothiazida 12 5mg)			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria APPROVED 2/07/201	Pollypill Version 1 (aspirin			
nd Pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria APPROVED 2/07/201	75mg, simvastatin 40mg,			
APPROVED 2/07/201 Some, simvastatin 40mg, sinopril 10mg, sinopril	lisinopril 10mg, atenolol 50mg)	for continuation of treatment of participants in Kanvini GAP Study (Protocol		
Some simulation 40mg, Sinopril 10mg,	and Pollypill Version 2 (aspirin		APPROVED	2/07/2012
avide chlorothiazide 12 5 mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg)	75mg, simvastatin 40mg,	7,00 0070) in decordance with study 3 approved inclusion and exclusion effective		
collypill Version 1 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, sino	lisinopril 10mg,			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 1	hydrochlorothiazida 12 5mg/			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin (Smg, simvastatin 40mg, sinopril 10mg, sinopril 10m				
APPROVED 2/07/201 X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria APPROVED 2/07/201				
X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria		for continuation of treatment of participants in Kanyini GAP Study (Protocol	A DDDOVED	2/07/2012
sinopril 10mg, sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria		X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Approximation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, Sinopril 10mg, atenology (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg,	75mg, simvastatin 40mg,			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, Sinopril 10mg, atenolol 50mg) APPROVED 2/07/201	lisinopril 10mg,			
5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenology of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg,	hudrochlorothiazida 12 5mg\ Pollypill Varsion 1 (aspirin			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg,				
nd Pollypill Version 2 (aspirin '5mg, simvastatin 40mg, sinopril 10mg, APPROVED 2/07/201	-			
5mg, simvastatin 40mg, sinopril 10mg,			APPROVED	2/07/2013
sinopril 10mg,		X08-0076) in accordance with study's approved inclusion and exclusion criteria	ATTROVED	2,01,2012

sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 3 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg)	Pollypill Version 1 (aspirin			
APPROVED 2/07/201 X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, without high state of participants in Kanyini GAP Study (Protocol Molypil Version 1 (aspirin Smg. simvastatin 40mg, sinopril 10mg, without high state of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, att	75mg, simvastatin 40mg,			
Sing, simvastatin 40mg, sinopril 10mg, withorship and the street of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) are continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076		for continuation of treatment of participants in Kanyini GAP Study (Protocol	A DDDOVED	2/07/2012
sinopril 10mg, survivatatin 40mg, sinopril 10mg, atenolol 50mg) and Polityill Version 1 (aspirin 55mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Polityill Version 2 (aspirin 55mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Polityill Version 10mg, sinopril 1		X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/0//2012
International Company of the Continuation of treatment of participants in Kanyini GAP Study (Protocol and Pollypill Version 1 (aspirin Smg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopr	75mg, simvastatin 40mg,			
collypill Version 1 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastati	lisinopril 10mg,			
Sing, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) in deposition of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopr				
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, sinopril 10				
APPROVED 2/07/201 Sing, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollybill Version 2 (aspirin 5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollybill Version 2 (aspirin 5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollybill Version 2 (aspirin 5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria approach to the study of				
Sing, simvastatin 40mg, sinopril 10mg, wideochlorabilasida 13 Employed inclusion and exclusion criteria (Sing, simvastatin 40mg, sinopril 10mg, set (Sinopril 10mg, sinopril 10mg, sinopri			APPROVED	2/07/2012
sinopril 10mg, withorbiographic side 12 5 mail of the process of t		X08-0076) in accordance with study's approved inclusion and exclusion criteria	7.1.11.0.12.5	2,07,2012
Interchalcosthiazida 12.5 Emb. (collapsil Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg)	-			
Sollypill Version 1 (aspirin Some, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) Ind Pollypill Version 2 (aspirin Some, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) Ind Pollypill Version 2 (aspirin Some, sinwastatin 40mg, sinopril 10mg,				
5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopri				
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, sinopril 1				
APPROVED 2/07/201 X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria		for continuation of treatment of narticipants in Kanvini CAD Study / Dratecal		
Sinopril 10mg, sinopr		·	APPROVED	2/07/2012
sinopril 10mg, wdoschlorathizaida 12.5ma) ollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg,		x08-0076) in accordance with study's approved inclusion and exclusion criteria		
ollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, simvastatin 40mg, sinopril 10mg, si	-			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, wateroble of the simple of the	hydrochlorothiazida 12 5mg)			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria APPROVED 2/07/201	Pollypill Version 1 (aspirin			
nd Pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria APPROVED 2/07/201	75mg, simvastatin 40mg,			
APPROVED 2/07/201 Some, simvastatin 40mg, sinopril 10mg, sinopril	lisinopril 10mg, atenolol 50mg)	for continuation of treatment of participants in Kanvini GAP Study (Protocol		
Some simulation 40mg, Sinopril 10mg,	and Pollypill Version 2 (aspirin		APPROVED	2/07/2012
avide chlorothiazide 12 5 mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg)	75mg, simvastatin 40mg,	7,00 0070) in decordance with study 3 approved inclusion and exclusion effective		
collypill Version 1 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, sino	lisinopril 10mg,			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 1	hydrochlorothiazida 12 5mg/			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin (Smg, simvastatin 40mg, sinopril 10mg, sinopril 10m				
APPROVED 2/07/201 X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria APPROVED 2/07/201				
X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria		for continuation of treatment of participants in Kanyini GAP Study (Protocol	A DDDOVED	2/07/2012
sinopril 10mg, sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria		X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Approximation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, Sinopril 10mg, atenology (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg,	75mg, simvastatin 40mg,			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, Sinopril 10mg, atenolol 50mg) APPROVED 2/07/201	lisinopril 10mg,			
5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenology of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg,	hudrochlorothiazida 12 5mg\ Pollypill Varsion 1 (aspirin			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg,				
nd Pollypill Version 2 (aspirin '5mg, simvastatin 40mg, sinopril 10mg, APPROVED 2/07/201	-			
5mg, simvastatin 40mg, sinopril 10mg,			APPROVED	2/07/2013
sinopril 10mg,		X08-0076) in accordance with study's approved inclusion and exclusion criteria	ATTROVED	2,01,2012

sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 3 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, witerschiantial 4.3.5mah collypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg)	Pollypill Version 1 (aspirin			
APPROVED 2/07/201 X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, without high state of participants in Kanyini GAP Study (Protocol Molypil Version 1 (aspirin Smg. simvastatin 40mg, sinopril 10mg, without high state of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, without high state of the study's approved inclusion and exclusion criteria sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, attended 50mg) and Pollypil Version 2 (aspirin Smg. sinwastatin 40mg, sinopril 10mg, att	75mg, simvastatin 40mg,			
Sing, simvastatin 40mg, sinopril 10mg, withorship and the street of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) are continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria Sing, simvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076		for continuation of treatment of participants in Kanyini GAP Study (Protocol	A DDDOVED	2/07/2012
sinopril 10mg, survivatatin 40mg, sinopril 10mg, atenolol 50mg) and Polityill Version 1 (aspirin 55mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Polityill Version 2 (aspirin 55mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Polityill Version 10mg, sinopril 1		X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/0//2012
International Company of the Continuation of treatment of participants in Kanyini GAP Study (Protocol and Pollypill Version 1 (aspirin Smg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopr	75mg, simvastatin 40mg,			
collypill Version 1 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5 mg, simvastati	lisinopril 10mg,			
Sing, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) in deposition of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopril 10mg, atenolol 50mg) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopr				
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill version 2 (aspirin 5mg, sinwastatin 40mg, sinopril 10mg, sinopril 10				
APPROVED 2/07/201 Sing, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollybill Version 2 (aspirin 5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollybill Version 2 (aspirin 5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollybill Version 2 (aspirin 5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria approach to the study of				
Sing, simvastatin 40mg, sinopril 10mg, wideochlorabilasida 13 Employed inclusion and exclusion criteria (Sing, simvastatin 40mg, sinopril 10mg, set (Sinopril 10mg, sinopril 10mg, sinopri			APPROVED	2/07/2012
sinopril 10mg, withorbiographic side 12 5 mail of the process of t		X08-0076) in accordance with study's approved inclusion and exclusion criteria	7.1.11.0.12.5	2,07,2012
Interchalcosthiazida 12.5 Emb. (collapsil Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria 3mopril 10mg, sinopril 10mg, atenolol 50mg)	-			
Sollypill Version 1 (aspirin Some, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) Ind Pollypill Version 2 (aspirin Some, sinwastatin 40mg, sinopril 10mg, atenolol 50mg) Ind Pollypill Version 2 (aspirin Some, sinwastatin 40mg, sinopril 10mg,				
5mg, sinvastatin 40mg, sinopril 10mg, atenolol 50mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, sinopri				
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, sinopril 10mg, atenolol 50mg) and pollypill Version 2 (aspirin 5mg, sinopril 1				
APPROVED 2/07/201 X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria		for continuation of treatment of narticipants in Kanvini CAD Study / Dratecal		
Sinopril 10mg, sinopr		·	APPROVED	2/07/2012
sinopril 10mg, wdoschlorathizaida 12.5ma) ollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg,		x08-0076) in accordance with study's approved inclusion and exclusion criteria		
ollypill Version 1 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, simvastatin 40mg, sinopril 10mg, si	-			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, wateroble of the simple of the	hydrochlorothiazida 12 5mg)			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria APPROVED 2/07/201	Pollypill Version 1 (aspirin			
nd Pollypill Version 2 (aspirin X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria APPROVED 2/07/201	75mg, simvastatin 40mg,			
APPROVED 2/07/201 Some, simvastatin 40mg, sinopril 10mg, sinopril	lisinopril 10mg, atenolol 50mg)	for continuation of treatment of participants in Kanvini GAP Study (Protocol		
Some simulation 40mg, Sinopril 10mg,	and Pollypill Version 2 (aspirin		APPROVED	2/07/2012
avide chlorothiazide 12 5 mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) For continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg)	75mg, simvastatin 40mg,	7,00 00707 in decordance with study 3 approved inclusion and exclusion effective		
collypill Version 1 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 15mg, simvastatin 40mg, sinopril 10mg, sino	lisinopril 10mg,			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, sinopril 1	hydrochlorothiazida 12 5mg/			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria (Smg, simvastatin 40mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin (Smg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin (Smg, simvastatin 40mg, sinopril 10mg, sinopril 10m				
APPROVED 2/07/201 X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria APPROVED 2/07/201				
X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria X08-0076) in accordance with study's approved inclusion and exclusion criteria		for continuation of treatment of participants in Kanyini GAP Study (Protocol	A DDDOVED	2/07/2012
sinopril 10mg, sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sydrochlorothiczide 12 5mg) sydrochlorothiczide 12 5mg) for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria		X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Approximation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, Sinopril 10mg, atenology (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg,	75mg, simvastatin 40mg,			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg, Sinopril 10mg, atenolol 50mg) APPROVED 2/07/201	lisinopril 10mg,			
5mg, simvastatin 40mg, sinopril 10mg, atenolol 50mg) nd Pollypill Version 2 (aspirin 5mg, simvastatin 40mg, sinopril 10mg, atenology of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg,	hudrochlorothiazida 12 5mg\ Pollypill Varsion 1 (aspirin			
for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria sinopril 10mg,				
nd Pollypill Version 2 (aspirin '5mg, simvastatin 40mg, sinopril 10mg, APPROVED 2/07/201	-			
5mg, simvastatin 40mg, sinopril 10mg,			APPROVED	2/07/2013
sinopril 10mg,		X08-0076) in accordance with study's approved inclusion and exclusion criteria	ATTROVED	2,01,2012

Pollypill Version 1 (aspirin			
75mg, simvastatin 40mg,			
lisinopril 10mg, atenolol 50mg)	for continuation of treatment of participants in Kanyini GAP Study (Protocol		2/27/224
and Pollypill Version 2 (aspirin	X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
75mg, simvastatin 40mg,			
lisinopril 10mg,			
hydrochlorothiazida 12 5ma)			
Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and	for continuation of treatment of participants in Kanyini GAP Study (Protocol	APPROVED	24/07/2012
Pollypill Version 2 (aspirin	X08-0076) in accordance with study's approved inclusion and exclusion criteria	ATTROVED	24/07/2012
75mg, simvastatin 40mg,			
lisinopril 10mg,			
Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and	for continuation of treatment of participants in Kanyini GAP Study (Protocol		
Pollypill Version 2 (aspirin		APPROVED	24/07/2012
75mg, simvastatin 40mg,	X08-0076) in accordance with study's approved inclusion and exclusion criteria		
lisinopril 10mg,			
hydrochlorothiazida 12 5mg)			
Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and	for continuation of treatment of participants in Kanyini GAP Study (Protocol		
Pollypill Version 2 (aspirin	X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/201
75mg, simvastatin 40mg,			
lisinopril 10mg,			
hydrochlorothiaaida 12 5mg)			
Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and	for continuation of treatment of participants in Kanyini GAP Study (Protocol	APPROVED	24/07/2012
Pollypill Version 2 (aspirin	X08-0076) in accordance with study's approved inclusion and exclusion criteria	ALLIOVED	24/0//2012
75mg, simvastatin 40mg,			
lisinopril 10mg,			
hydrochlorothiazide 12 5mg) Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and			
Pollypill Version 2 (aspirin	for continuation of treatment of participants in Kanyini GAP Study (Protocol	APPROVED	24/07/2012
75mg, simvastatin 40mg,	X08-0076) in accordance with study's approved inclusion and exclusion criteria		• •
lisinopril 10mg,			
hydrochlorothiazida 12 5mg\			

Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg,		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, bydrochlorothiazide 12 5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg,		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Mifepristone		for medical abortion in first trimester (up to 63 days), medical abortion in 2nd trimester (up to 17 weeks), cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	19/06/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	for treatment of preterm who have a gestational age at birth of less than 32 weeks or birth weight less than 1500 grams and on enteral feed for at least 48 hours for prevention of necrotising enterocolitis (NEC)	APPROVED	24/07/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	for treatment of preterm who have a gestational age at birth of less than 32 weeks or birth weight less than 1500 grams and on enteral feed for at least 48 hours for prevention of necrotising enterocolitis (NEC)	APPROVED	24/07/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	for treatment of preterm who have a gestational age at birth of less than 32 weeks or birth weight less than 1500 grams and on enteral feed for at least 48 hours for prevention of necrotising enterocolitis (NEC)	APPROVED	24/07/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	for treatment of preterm who have a gestational age at birth of less than 32 weeks or birth weight less than 1500 grams and on enteral feed for at least 48 hours for prevention of necrotising enterocolitis (NEC)	APPROVED	24/07/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	for treatment of preterm who have a gestational age at birth of less than 32 weeks or birth weight less than 1500 grams and on enteral feed for at least 48 hours for prevention of necrotising enterocolitis (NEC)	APPROVED	24/07/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	for treatment of preterm who have a gestational age at birth of less than 32 weeks or birth weight less than 1500 grams and on enteral feed for at least 48 hours for prevention of necrotising enterocolitis (NEC)	APPROVED	24/07/2012
Mifepristone		for medical abortion in first trimester	APPROVED	17/07/2012

clobetasol	to treat dermatoses that are non-responsive to weaker topical steroids eg psoriasis, eczema, cutaneous lupus, lichen planus, pyoderma gangrenosum and other potentially resistant less common dermatoses	APPROVED	29/08/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg,	for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, bydrochlorothiazide 12 5mg)	for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, bydrochlorothiazide 12 5mg)	for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, bydrochlorothiazide 12 5mg)	for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, bydrochlorothiazide 12 5mg)	for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012

Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril	for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria		
10mg, atenolol 50mg) and		APPROVED	24/07/2012
Pollypill Version 2 (aspirin		AFFROVED	24/07/2012
75mg, simvastatin 40mg,			
lisinopril 10mg,			
Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and	for any time of the attention of the attinion of the string of the strin		
Pollypill Version 2 (aspirin	for continuation of treatment of participants in Kanyini GAP Study (Protocol	APPROVED	24/07/2012
75mg, simvastatin 40mg,	X08-0076) in accordance with study's approved inclusion and exclusion criteria		
lisinopril 10mg,			
hydrochlorothiazida 12 5mg)			
Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and	for continuation of treatment of participants in Kanyini GAP Study (Protocol		
Pollypill Version 2 (aspirin	X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
75mg, simvastatin 40mg,			
lisinopril 10mg,			
hydrochlorothiazida 12 5mg)			
Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and	for continuation of treatment of participants in Kanyini GAP Study (Protocol	APPROVED	24/07/2012
Pollypill Version 2 (aspirin	X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
75mg, simvastatin 40mg,			
lisinopril 10mg,			
Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and			
Pollypill Version 2 (aspirin	for continuation of treatment of participants in Kanyini GAP Study (Protocol	APPROVED	24/07/2012
75mg, simvastatin 40mg,	X08-0076) in accordance with study's approved inclusion and exclusion criteria		
lisinopril 10mg,			
hydrochlorothiazide 12 5mg/			
Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and	for continuation of treatment of participants in Kanyini GAP Study (Protocol		
Pollypill Version 2 (aspirin	X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
75mg, simvastatin 40mg,	and so, of masser and the stant of approved monastin and exclusion official		
lisinopril 10mg,			
hudrochlorothiazida 12 5mal			

Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril	for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria		
10mg, atenolol 50mg) and		APPROVED	24/07/2012
Pollypill Version 2 (aspirin		AFFROVED	24/07/2012
75mg, simvastatin 40mg,			
lisinopril 10mg,			
Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and	for anythmetical of the standard of anything arts in Many ini CAR Charles (Basteral		
Pollypill Version 2 (aspirin	for continuation of treatment of participants in Kanyini GAP Study (Protocol	APPROVED	24/07/2012
75mg, simvastatin 40mg,	X08-0076) in accordance with study's approved inclusion and exclusion criteria		
lisinopril 10mg,			
hydrochlorothiazide 12 5mg)			
Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and	for continuation of treatment of participants in Kanyini GAP Study (Protocol		
Pollypill Version 2 (aspirin	X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
75mg, simvastatin 40mg,			
lisinopril 10mg,			
hydrochlorothiazida 12 5mg)			
Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and	for continuation of treatment of participants in Kanyini GAP Study (Protocol	APPROVED	24/07/2012
Pollypill Version 2 (aspirin	X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
75mg, simvastatin 40mg,			
lisinopril 10mg,			
Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and			
Pollypill Version 2 (aspirin	for continuation of treatment of participants in Kanyini GAP Study (Protocol	APPROVED	13/09/2012
75mg, simvastatin 40mg,	X08-0076) in accordance with study's approved inclusion and exclusion criteria		
lisinopril 10mg,			
hydrochlorothiazide 12 Smal			
Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and	for continuation of treatment of participants in Kanyini GAP Study (Protocol		
Pollypill Version 2 (aspirin	X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
75mg, simvastatin 40mg,	1.00 007 07 in accordance with study 5 approved inclusion and exclusion effective		
lisinopril 10mg,			
hydrochlorothiazida 12 5mg)			

Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg,		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
lisinopril 10mg, hydrochlorothiazida 12 5mg/ Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg,		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Progesterone (Utrogestan) 100mg & 200mg capsules	Utrogestan	for short term treatment of oestrogen deficiency symptoms in women with an intact uterus	APPROVED	6/08/2012
clobetasol		Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus) conditions	APPROVED	29/08/2012
clobetasol		Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus) conditions	APPROVED	29/08/2012
clobetasol		Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus) conditions	APPROVED	29/08/2012
Multiple Allergens - Alyostal		Skin prick testing for diagnostic allergy testing	APPROVED	10/08/2012
Multiple Allergens - Alyostal		Skin prick testing for diagnostic allergy testing	APPROVED	10/08/2012
Multiple Allergen SkinTest Reagents - ALK Abello		Skin prick testing for diagnostic allergy testing	APPROVED	31/07/2012
Diater DAP Penicillin and Amoxycillin SkinTest Reagents		for skin testing to investigate allergy to beta-lactam antibiotics	APPROVED	10/08/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	31/07/2012
Indocyanine Green	·	Suspected polypoidal choroidal vasculopathy	APPROVED	31/07/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	23/08/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	10/08/2012

Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril	for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	10/08/2012
10mg, hydrochlorothiazide 12 5mg/ Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg,	for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	10/08/2012
hydrochlorothiazide 12 5mg/ Multiple Allergen Skin Test Reagents (Alyostal)	for skin prick testing for allergy testing.	APPROVED	2/08/2012
Multiple Allergen Skin Test Reagents (ALK-Abellol)	for skin prick testing for diagnostic allergy testing.	APPROVED	2/08/2012
Diater DAP Skin Prick Testing Reagents	for skin prick testing for penicillin and amoxycillin allergy testing.	APPROVED	2/08/2012
cholecalciferol	moderate to severe vitamin D deficiency	APPROVED	29/08/2012
cholecalciferol	moderate to severe vitamin D deficiency	APPROVED	29/08/2012
cholecalciferol	moderate to severe vitamin D deficiency	APPROVED	29/08/2012
cholecalciferol	moderate to severe vitamin D deficiency	APPROVED	29/08/2012
cholecalciferol	moderate to severe vitamin D deficiency	APPROVED	29/08/2012
cholecalciferol	moderate to severe vitamin D deficiency	APPROVED	29/08/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012

Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
methacholine	Provocholine	for bronchial hyperresponsiveness testing for diagnosis of asthma	APPROVED	10/08/2012
methacholine	Provociionne	in palliative care patients to treat nausea, vomiting, delirium and terminal	APPROVED	10/06/2012
Levomepromazine		agitation	APPROVED	10/08/2012
Levomepromazine		in palliative care patients to treat nausea, vomiting, delirium and terminal agitation	APPROVED	10/08/2012
cholecalciferol		for treatment of moderate to severe Vitamin D deficiency	APPROVED	10/08/2012
melatonin 3mg immediate		for treatment of sleep disturbances in ocularly blind children	APPROVED	7/09/2012
release capsules		for treatment of sleep disturbances in occitany billio children	APPROVED	7/09/2012
Multiple Allergen Skin Test		for skin prick testing for allergies	ADDDOVED	14/09/2012
Reagents (ALK-Abello)		for skin prick testing for allergies	APPROVED	14/09/2012
ALK-Abello Human Serum				
Albumin with Phenol (HSA)		for skin prick testing for allergies	APPROVED	14/09/2012
diluent				
Diater DAP Penicillin and				
Amoxycillin Skin Test Reagents		for skin prick testing for allergies	APPROVED	14/09/2012
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	25/09/2012
Multiple Allergen Skin Test		skin prick testing for allergies	APPROVED	22/08/2012
Reagents				•

Multiple Allergen Skin Test Reagents	skin prick testing for allergies	APPROVED	22/08/2012
Mifepristone	Medical abortion when this is assessed as the best clinical option for the individual woman	APPROVED	3/09/2012
Mifepristone	Medical abortion when this is assessed as the best clinical option for the individual woman	APPROVED	3/09/2012
Mifepristone	Medical abortion when this is assessed as the best clinical option for the individual woman	APPROVED	3/09/2012
Mifepristone	Termination of pregnancy where medical abortion is assessed as the best clinical option for the individual woman.	APPROVED	3/09/2012
Mifepristone	Termination of pregnancy where medical abortion is assessed as the best clinical option for the individual woman.	APPROVED	3/09/2012
Diater DAP-kit [penicilloyl-poly- L (PPL) and minor determinant mixture (MDM)]	for penicllin allergy skin prick testing	APPROVED	23/08/2012
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing for allergies	APPROVED	7/09/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)	skin prick testing for allergies	APPROVED	7/09/2012
ALK-Abello Human Serum Albumin with Phenol (HSA) diluent	skin prick testing for allergies	APPROVED	7/09/2012
ALK-Abello Normal Saline with Phenol (NSP) diluent	skin prick testing for allergies	APPROVED	7/09/2012
Cholecystokinin	nuclear medicine imaging for patients with gall bladder disease	APPROVED	23/08/2012
melatonin 5mg immediate release tablets	conditions where sleep patterns are disrupted, including those secondary to intellectual impairment, developmental delay or autism that are non responsive to hypnotics or sedatives	APPROVED	7/09/2012
cholecalciferol	moderate to severe vitamin D deficiency	APPROVED	23/08/2012
cholecalciferol	moderate to severe vitamin D deficiency	APPROVED	23/08/2012
cholecalciferol	moderate to severe vitamin D deficiency	APPROVED	23/08/2012
cholecalciferol	moderate to severe vitamin D deficiency	APPROVED	23/08/2012
cholecalciferol	moderate to severe vitamin D deficiency	APPROVED	23/08/2012
cholecalciferol	moderate to severe vitamin D deficiency	APPROVED	23/08/2012
cholecalciferol	moderate to severe vitamin D deficiency	APPROVED	23/08/2012
cholecalciferol	moderate to severe vitamin D deficiency	APPROVED	23/08/2012
Ethinyloestradiol	to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Dydrogesterone (Duphaston) 10mg	uterine protection while on Oestrogen	APPROVED	28/08/2012
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing for allergies	APPROVED	29/08/2012
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing for allergies	APPROVED	7/09/2012

Testosterone Implant 75mg	Testopel Implant 75mg	management of hypoactive sexual desire disorder in postmenopausal women and women in their late reproductive years	APPROVED	7/09/2012
Indocyanine Green		investigation of retinal disease and tissue stain during vitrectomy	APPROVED	29/08/2012
Cyclizine 50mg tablets		nausea and vomitting in Palliative Care patients	APPROVED	3/09/2012
Levomepromazine tablets and ampoules		nausea and vomitting in Palliative Care patients	APPROVED	3/09/2012
Indocyanine Green		during retinal/choroidal angiography	APPROVED	29/08/2012
Indocyanine Green		during retinal/choroidal angiography	APPROVED	29/08/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	29/08/2012
L-Carnitine (intravenous)		inborn errors of metabolism, fatty acid oxidation and organic acidaemias	APPROVED	18/12/2012
Arginine (intravenous)		hyperammonaemia and urea cycle disorders	APPROVED	18/12/2012
L-Carnitine (intravenous)		inborn errors of metabolism, fatty acid oxidation and organic acidaemias	APPROVED	18/12/2012
Arginine (intravenous)		hyperammonaemia and urea cycle disorders	APPROVED	18/12/2012
Bifidobacterium infantis & Lactobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	7/09/2012
enalaprilat		for use in renal venous renin ratio testing for patients undergoing renal venous ratio studies	APPROVED	7/09/2012
clobetasol		Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus)	APPROVED	29/08/2012
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for diagnostic allergy testing	APPROVED	16/05/2013
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	6/09/2012
mannitol	Bronchitol	bronchiectasis	APPROVED	6/09/2012
cholecystekinin		as a diagnostic test agent for investigation of biliary disorders	APPROVED	6/09/2012
cholecystekinin		as a diagnostic test agent for investigation of biliary disorders	APPROVED	6/09/2012
cholecystekinin		as a diagnostic test agent for investigation of biliary disorders	APPROVED	6/09/2012
cholecystekinin		as a diagnostic test agent for investigation of biliary disorders	APPROVED	6/09/2012
cholecystekinin		as a diagnostic test agent for investigation of biliary disorders	APPROVED	6/09/2012
Ethinyloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	14/09/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	14/09/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	14/09/2012

Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	10/09/2012
Multiple Allergen Skin Test				
Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	14/09/2012
Multiple Allergen Skin Test				
Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	14/09/2012
Polypill Version 1 (aspirin 75mg,				
simvastatin 40mg, lisinopril				
10mg, atenolol 50mg) and				
Pollypill Version 2 (aspirin		for continuation of treatment of participants in Kanyini GAP Study (Protocol	APPROVED	13/09/2012
75mg, simvastatin 40mg,		X08-0076) in accordance with study's approved inclusion and exclusion criteria		
isinopril 10mg,				
ovdrochlorothiszide 12 5mg/				
Polypill Version 1 (aspirin 75mg,				
simvastatin 40mg, lisinopril				
10mg, atenolol 50mg) and		for continuation of treatment of participants in Kanyini GAP Study (Protocol		
Pollypill Version 2 (aspirin			APPROVED	13/09/2012
75mg, simvastatin 40mg,		X08-0076) in accordance with study's approved inclusion and exclusion criteria		
isinopril 10mg,				
avdrochlorothiazida 12 5mgl				
oyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	25/09/2012
oyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	25/09/2012
oyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	25/09/2012
oyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	25/09/2012
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	25/09/2012
oyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	25/09/2012
Polypill Version 1 (aspirin 75mg,	,			
simvastatin 40mg, lisinopril				
10mg, atenolol 50mg) and		for continuation of treatment of participants in Kanyini GAP Study (Protocol		
Pollypill Version 2 (aspirin		X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	25/09/2012
75mg, simvastatin 40mg,		700-00707 III accordance with study's approved inclusion and exclusion criteria		
isinopril 10mg,				
hydrochlorothizzida 12 5mal				
cholecalciferol		moderate to severe vitamin D deficiency	APPROVED	25/09/2012
cholecalciferol		moderate to severe vitamin D deficiency	APPROVED	25/09/2012
cholecalciferol		moderate to severe vitamin D deficiency	APPROVED	25/09/2012
Perflutren Protein-Type A				
Microspheres Injectable	Optison	contrast agent for non-diagnostic echocardiogram	APPROVED	2/10/2012
Suspension				
Perflutren Protein-Type A				, .
Microspheres Injectable	Optison	contrast agent for non-diagnostic echocardiogram	APPROVED	2/10/2012
Suspension				
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG	APPROVED	25/09/2012
,		angiography		-,,

Indocyanine Green	during vitreo-retinal surgery and for intravenous injection to perform ICG	APPROVED	25/09/2012
	angiography during vitreo-retinal surgery and for intravenous injection to perform ICG		
Indocyanine Green	angiography	APPROVED	25/09/2012
	patients in whom the registered product is unsuitable with conditions where		
melatonin 3mg controlled	sleep patterns are disrupted, including those secondary to intellectual	APPROVED	11/10/2012
release capsules	impairment, developmental delay or autism that are non responsive to	ATTROVED	11/10/2012
	hypnotics or sedatives		
Indocyanine Green	for use during vitreo-retinal surgery and for intravenous injection to perform	APPROVED	10/10/2012
madeyanine Green	ICG angiography	, II I NO VED	10/10/2012
Gonadorelin (100 mcg injection)	to assess the pituitary gonadotropin response in disorders of puberty or	APPROVED	16/10/2012
Genderen (100 meg mjestom)	gonadal function	711110022	10, 10, 2012
Gonadorelin (100 mcg injection)	to assess the pituitary gonadotropin response in disorders of puberty or	APPROVED	16/10/2012
German (100 mag mjestion)	gonadal function	711110022	10, 10, 2012
Gonadorelin (100 mcg injection)	to assess the pituitary gonadotropin response in disorders of puberty or	APPROVED	16/10/2012
dender ein (100 meg mjeetion)	gonadal function	, II I NO VED	10/10/2012
Gonadorelin (100 mcg injection)	to assess the pituitary gonadotropin response in disorders of puberty or	APPROVED	16/10/2012
Gondalin (100 meg mjection)	gonadal function	ATTROVED	10/10/2012
Gonadorelin (100 mcg injection)	to assess the pituitary gonadotropin response in disorders of puberty or	APPROVED	16/10/2012
Gernadoremi (100 meg mjedaom)	gonadal function	711110022	10, 10, 2012
Gonadorelin (100 mcg injection)	to assess the pituitary gonadotropin response in disorders of puberty or	APPROVED	16/10/2012
Gernadoremi (100 meg mjedaom)	gonadal function	711110022	10, 10, 2012
Gonadorelin (100 mcg injection)	to assess the pituitary gonadotropin response in disorders of puberty or	APPROVED	16/10/2012
Gernadoremi (100 meg mjedaom)	gonadal function	711110022	10, 10, 2012
Gonadorelin (100 mcg injection)	to assess the pituitary gonadotropin response in disorders of puberty or	APPROVED	16/10/2012
· • • • •	gonadal function		
triamcinolone hexacetonide	juvenile idiopathic arthritis	APPROVED	11/10/2012
triamcinolone hexacetonide	juvenile idiopathic arthritis	APPROVED	11/10/2012
triamcinolone hexacetonide	juvenile idiopathic arthritis	APPROVED	11/10/2012
triamcinolone hexacetonide	juvenile idiopathic arthritis	APPROVED	11/10/2012
triamcinolone hexacetonide	juvenile idiopathic arthritis	APPROVED	11/10/2012
Polypill Version 1 (aspirin 75mg,			
simvastatin 40mg, lisinopril			
10mg, atenolol 50mg) and	for continuation of treatment of participants in Kanyini GAP Study (Protocol		
Pollypill Version 2 (aspirin	X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	11/10/2012
75mg, simvastatin 40mg,	The secondaries with study suppressed metasion and exclusion effective		
lisinopril 10mg,			
hydrochlorothiazida 12 5mg)			

Polypill Version 1 (aspirin 75mg	g,			
simvastatin 40mg, lisinopril				
10mg, atenolol 50mg) and		for continuation of treatment of participants in Kanyini GAP Study (Protocol		
Pollypill Version 2 (aspirin		X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	11/10/2012
75mg, simvastatin 40mg,		700 0070) In accordance with study 3 approved inclusion and exclusion effectia		
isinopril 10mg,				
hydrochlorothiazida 12 5mgl				
Multiple Allergen Skin Test		skin prick testing for diagnosis of allergies	APPROVED	17/01/2013
Reagents (Alyostal)				
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	10/10/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	10/10/2012
Multiple Allergen Skin Test		skin prick testing for allergies	APPROVED	11/10/2012
Reagents (Alyostal)				
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
0.6% Intracameral Syringe				• •
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
0.6% Intracameral Syringe				
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
0.6% Intracameral Syringe				, ,
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
0.6% Intracameral Syringe				
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
0.6% Intracameral Syringe		117 7 1 0 0 7		
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
0.6% Intracameral Syringe		117 7 1 0 0 7		
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
0.6% Intracameral Syringe		, , , , , , , , , , , , , , , , , , ,		-, -, -
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
0.6% Intracameral Syringe		, , , , , , , , , , , , , , , , , , ,		-, -, -
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
0.6% Intracameral Syringe		, , , , , , , , , , , , , , , , , , ,		-, -, -
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
0.6% Intracameral Syringe				,,
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
0.6% Intracameral Syringe				,,
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
0.6% Intracameral Syringe				,,
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
0.6% Intracameral Syringe				10, 10, 2012
Multiple Allergen Skin Test		skin prick testing for allergies	APPROVED	11/10/2012
Reagents (Alyostal)				
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	10/10/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	10/10/2012

Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for diagnosis of allergies	APPROVED	17/01/2013
Multiple Allergen Skin Test				
Reagents (Alyostal)		skin prick testing for diagnosis of allergies	APPROVED	17/01/2013
Multiple Allergen Skin Test				
Reagents (ALK-Abello)		skin prick testing for diagnosis of allergies	APPROVED	17/01/2013
Multiple Allergen Skin Test				
Reagents (ALK-Abello)		skin prick testing for diagnosis of allergies	APPROVED	17/01/2013
Multiple Allergen Skin Test				
=		skin prick testing for diagnosis of allergies	APPROVED	17/01/2013
Reagents (Alyostal) Multiple Allergen Skin Test				
	ALK-Abello	for skin prick testing for allergy testing	APPROVED	12/02/2013
Reagents (ALK-Abello)				
Multiple Allergen Skin Test	Alyostal	for skin prick testing for allergy testing	APPROVED	12/02/2013
Reagents (Alyostal)				
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG	APPROVED	27/11/2012
		angiography		
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	19/10/2012
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	19/10/2012
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	19/10/2012
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	22/10/2012
flunarizine		Neurological Conditions such as migrane, hemiplegia, cerebral vasculopathy and Moya Moya Syndrome	APPROVED	19/10/2012
fl a winin a		Neurological Conditions such as migrane, hemiplegia, cerebral vasculopathy	APPROVED	10/10/2012
flunarizine		and Moya Moya Syndrome	APPROVED	19/10/2012
fl a wining a		Neurological Conditions such as migrane, hemiplegia, cerebral vasculopathy	ADDDOVED	10/10/2012
flunarizine		and Moya Moya Syndrome	APPROVED	19/10/2012
Stiripentol	stiripentol	severe myoclonic epilepsy in infancy (Dravet syndrome)	APPROVED	31/10/2012
Multiple Allergen Skin Test				
Reagents (ALK-Abello)	Multiple allergen extracts	Skin prick testing for diagnostic allergy testing	APPROVED	19/10/2012
Multiple Allergen Skin Test				
Reagents (Alyostal)	Multiple allergen extracts	Skin prick testing for diagnostic allergy testing	APPROVED	19/10/2012
Oestradiol (Estrapel) sub		releif of vasomotor and other symptoms of oestrogen deficiency in menopausal	APPROVED	10/01/2013
cutaneous pellets 25mg & 50mg		and perimenopausal women		-, - ,
0 1 1 1/5 1 2 1				
Oestradiol (Estrapel) sub		releif of vasomotor and other symptoms of oestrogen deficiency in menopausal	APPROVED	4/04/2013
cutaneous pellets 25mg & 50mg		and perimenopausal women		, , , , ,
Progesterone (Utrogestan)		endometrial protection in post menopausal women on systemic oestrogen	APPROVED	19/10/2012
100mg & 200mg		therapy	AFFRUVED	19/10/2012
Dydrogesterone (Duphaston)		endometrial protection in post menopausal women on systemic oestrogen	ADDDOVED	10/10/2011
10mg		therapy	APPROVED	19/10/2012
	Mifoguno	first trimester miscarriage, fetal abnormality, fetal death in utero, maternal	ADDROVED	15/04/2041
mifepristone	Mifegyne	illness, extreme premature prelabour rupture of membranes	APPROVED	15/01/2013

mifepristone	Mifegyne	first trimester miscarriage, fetal abnormality, fetal death in utero, maternal illness, extreme premature prelabour rupture of membranes	APPROVED	15/01/2013
mifepristone	Mifegyne	first trimester miscarriage, fetal abnormality, fetal death in utero, maternal illness, extreme premature prelabour rupture of membranes	APPROVED	15/01/2013
mifepristone	Mifegyne	first trimester miscarriage, fetal abnormality, fetal death in utero, maternal illness, extreme premature prelabour rupture of membranes	APPROVED	15/01/2013
mifepristone	Mifegyne	first trimester miscarriage, fetal abnormality, fetal death in utero, maternal illness, extreme premature prelabour rupture of membranes	APPROVED	15/01/2013
mifepristone	Mifegyne	first trimester miscarriage, fetal abnormality, fetal death in utero, maternal illness, extreme premature prelabour rupture of membranes	APPROVED	15/01/2013
mifepristone	Mifegyne	first trimester miscarriage, fetal abnormality, fetal death in utero, maternal illness, extreme premature prelabour rupture of membranes	APPROVED	15/01/2013
Multiple Allergen Skin Test Reagents (Alyostal)		allergy skin prick testing	APPROVED	13/12/2012
Multiple Allergen Skin Prick Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	19/10/2012
Multiple Allergen Skin Prick Test Reagents (ALK-Abellol)		for skin prick testing for allergies	APPROVED	19/10/2012
Diater DAP Amoxycillin and Penicillin Skin Prick Test Reagents		for skin prick testing for allergies	APPROVED	29/10/2012
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	27/11/2012
Progesterone (Utrogestan) 100mg & 200mg		endometrial protection in post menopausal women on systemic oestrogen therapy	APPROVED	28/11/2012
Dydrogesterone (Duphaston) 10mg		endometrial protection in post menopausal women on systemic oestrogen therapy	APPROVED	27/11/2012
flunarizine		neurological conditions such as migrane, hemiplegia, cerebral vasculopathy, Moya Moya Syndrome	APPROVED	31/10/2012
Indocyanine Green		for intravenous injection to perform ICG angiography	APPROVED	25/10/2012
ndocyanine Green		for intravenous injection to perform ICG angiography	APPROVED	25/10/2012
ndocyanine Green		for intravenous injection to perform ICG angiography	APPROVED	25/10/2012
triamcinolone hexacetonide		for intra-articular therapy in juvenile idiopathic arthritis	APPROVED	27/11/2012
triamcinolone hexacetonide		for intra-articular therapy in juvenile idiopathic arthritis	APPROVED	27/11/2012
triamcinolone hexacetonide		for intra-articular therapy in juvenile idiopathic arthritis	APPROVED	27/11/2012
glycopyrronium bromide 0.05%	glycopyronium bromide	for the treatment of palmo and plantar hyperhidrosis	APPROVED	27/11/2012
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	27/11/2012
Diater (DAP) Determinants Allergy Penicillin	penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)	skin testing for penicillin allergy	APPROVED	31/10/2012

cholecalciferol IM injection	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
100,000 IU/mL (D3-Vicotrat) cholecalciferol IM injection			
300,000 IU/mL (Vitamine D3	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
	Severe vitaliili b deliciency (serdili 25-liydroxyvitaliili b \50111101/L)	AFFROVED	31/10/2012
Steuli) cholecalciferol IM injection			
100,000 IU/mL (D3-Vicotrat)	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection			
300,000 IU/mL (Vitamine D3	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
	Severe vitamin b denciency (serum 25-nydroxyvitamin b (50mno)/L)	AITROVED	31/10/2012
Steuli) cholecalciferol IM injection			
100,000 IU/mL (D3-Vicotrat)	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection			
-	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
300,000 IU/mL (Vitamine D3	Severe vitaliili D delicielicy (serulli 25-liydroxyvitaliiii D <50liiliol/L)	APPROVED	31/10/2012
Steuli)			
cholecalciferol IM injection	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
100,000 IU/mL (D3-Vicotrat)			
cholecalciferol IM injection	Nitaria Dalafisia and James 25 hadron aitaria Da 200 and 1/1	APPROVED	21/10/2012
300,000 IU/mL (Vitamine D3	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
Steuli)			
cholecalciferol IM injection	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
100,000 IU/mL (D3-Vicotrat)			
cholecalciferol IM injection			
300,000 IU/mL (Vitamine D3	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
Steuli)			
cholecalciferol IM injection	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
100,000 IU/mL (D3-Vicotrat)			- , -, -
cholecalciferol IM injection			
300,000 IU/mL (Vitamine D3	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
Steuli)			
cholecalciferol IM injection	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
100,000 IU/mL (D3-Vicotrat)			,,
cholecalciferol IM injection			
300,000 IU/mL (Vitamine D3	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
Steuli)			
cholecalciferol IM injection	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
100,000 IU/mL (D3-Vicotrat)	Servere thamms demoising (Seram 25 Hydroxythamms Sommon, 2)	,	31, 10, 2012
cholecalciferol IM injection			
300,000 IU/mL (Vitamine D3	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
Steuli)			
cholecalciferol IM injection	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
100,000 IU/mL (D3-Vicotrat)	Severe vitalilii b denciency (serulii 25-liyuroxyvitalilii b \30111101/L)	ALLINOVED	31/10/2012

cholecalciferol IM injection	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
300,000 IU/mL (Vitamine D3 Steuli)	Severe vitamin b denciency (serum 23-nydroxyvitamin b <30mio/, L)	APPROVED	31/10/2012
cholecalciferol IM injection	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
100,000 IU/mL (D3-Vicotrat)	2010.0 11.0 11.0 2010.0 11.0 11.0 11.0 1	7 11 11 10 122	01,10,1011
cholecalciferol IM injection			
300,000 IU/mL (Vitamine D3	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
Steuli)			
cholecalciferol IM injection	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
100,000 IU/mL (D3-Vicotrat)	* * * * * * * * * * * * * * * * * * * *		
cholecalciferol IM injection)	4 DDD 01/5D	24 /40 /2042
300,000 IU/mL (Vitamine D3	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
Steuli)			
cholecalciferol IM injection	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
100,000 IU/mL (D3-Vicotrat)			
cholecalciferol IM injection	covere Vitamin D deficiency (corum 25 by drawwitamin D 220mm 1/1)	ADDROVED	24 /40 /2042
300,000 IU/mL (Vitamine D3	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
Steuli)			
cholecalciferol IM injection	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
100,000 IU/mL (D3-Vicotrat)			
cholecalciferol IM injection	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2013
300,000 IU/mL (Vitamine D3	Severe vitaliili b deliciency (serulii 25-liydroxyvitaliilii b \30111101/L)		
Steuli) cholecalciferol IM injection			
100,000 IU/mL (D3-Vicotrat)	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection			
300,000 IU/mL (Vitamine D3	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
Steuli)			,,
cholecalciferol IM injection			
100,000 IU/mL (D3-Vicotrat)	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection			
300,000 IU/mL (Vitamine D3	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
Steuli)			
cholecalciferol IM injection	Note that D. J. Friedrich and J. D. 200 (1/1)	ADDDOVED	24 /40 /2042
100,000 IU/mL (D3-Vicotrat)	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection			
300,000 IU/mL (Vitamine D3	severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
Steuli)			
cholecalciferol (Cal D Forte)	moderate to covere Vitamin D deficiency	ADDROVED	27/11/2012
1.25mg or 50,000 IU	moderate to severe Vitamin D deficiency	APPROVED	2//11/2012
cholecalciferol 1.25mg (50,000	for the treatment of moderate to severe Vitamin D deficiency	APPROVED	14/11/2012
iu)	Tor the treatment of moderate to severe vitamin D dentiency	AFFRUVED	14/11/2012

Bifidobacterium infantis & Lactobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	14/11/2012
Bifidobacterium infantis & Lactobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	14/11/2012
Bifidobacterium infantis & actobacillus actobacillus	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	14/11/2012
Bifidobacterium infantis & actobacillus	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	14/11/2012
Bifidobacterium infantis & actobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	15/11/2012
Bifidobacterium infantis & actobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	14/11/2012
Bifidobacterium infantis & actobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	14/11/2012
Bifidobacterium infantis & .actobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	14/11/2012
Penicillin Allergy Determinants DAP) - Diater	penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)	for testing and identification of drug allergy to beta lactam antibiotics	APPROVED	27/11/2012
Penicillin Allergy Determinants DAP) - Diater	penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)	for testing and identification of drug allergy to beta lactam antibiotics	APPROVED	27/11/2012
Multiple Allergen skin Test Reagents (Alyostal)	Alyostal Skin testing reagents	skin prick testing for diagnosis of allergies allergies	APPROVED	28/11/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	skin prick testing for diagnosis of allergies	APPROVED	27/11/2012
Diater DAP Penicillin and Amoxycillin Skin Prick Test Reagents		skin prick testing for diagnosis of penicillin and amoxycillin allergies	APPROVED	27/11/2012
Diater DAP Penicillin and Amoxycillin Skin Prick Test Reagents		skin prick testing for diagnosis of penicillin and amoxycillin allergies	APPROVED	27/11/2012

Diater DAP Penicillin and				
Amoxycillin Skin Prick Test		skin prick testing for diagnosis of penicillin and amoxycillin allergies	APPROVED	27/11/2012
Reagents				
Diater DAP Penicillin and				
Amoxycillin Skin Prick Test		skin prick testing for diagnosis of penicillin and amoxycillin allergies	APPROVED	27/11/2012
Reagents				
Diater DAP Penicillin and				
Amoxycillin Skin Prick Test		skin prick testing for diagnosis of penicillin and amoxycillin allergies	APPROVED	14/12/2012
Reagents				
Diater DAP Penicillin and				
Amoxycillin Skin Prick Test		skin prick testing for diagnosis of penicillin and amoxycillin allergies	APPROVED	27/11/2012
Reagents				
Multiple Allergen Skin Test	ALK-Abello	chin prick testing for diagnosis of allowing	ADDDOVED	27/11/2011
Reagents (ALK-Abello)	ALK-ADEIIO	skin prick testing for diagnosis of allergies	APPROVED	27/11/2012
Multiple Allergen Skin Test	ALK Aballa	chin prick testing for diagnosis of allowing	ADDDOVED	27/11/2011
Reagents (ALK-Abello)	ALK-Abello	skin prick testing for diagnosis of allergies	APPROVED	27/11/2012
Multiple Allergen Skin Test	ALK Aballa	chin prick testing for diagnosis of allows	ADDDOV/ED	27/44/2041
Reagents (ALK-Abello)	ALK-Abello	skin prick testing for diagnosis of allergies	APPROVED	27/11/201
Multiple Allergen skin Test	Alyostal Skin testing	1	400001/50	20/44/204
Reagents (Alyostal)	reagents	skin prick testing for diagnosis of allergies allergies	APPROVED	28/11/201
Multiple Allergen skin Test	Alyostal Skin testing		100001150	20/44/2044
Reagents (Alyostal)	reagents	skin prick testing for diagnosis of allergies allergies	APPROVED	28/11/201
Multiple Allergen skin Test	Alyostal Skin testing		100001150	20/11/2011
Reagents (Alyostal)	reagents	skin prick testing for diagnosis of allergies allergies	APPROVED	28/11/2012
Multiple Allergen skin Test	Alyostal Skin testing			//
Reagents (Alyostal)	reagents	skin prick testing for diagnosis of allergies allergies	APPROVED	28/11/2012
Multiple Allergen skin Test	Alyostal Skin testing			
Reagents (Alyostal)	reagents	skin prick testing for diagnosis of allergies allergies	APPROVED	28/11/2012
	100,000	Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical		
Mifepristone		abortion in 1st and 2nd trimesters	APPROVED	21/12/2012
		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical		
Mifepristone		abortion in 1st and 2nd trimesters	APPROVED	21/12/2012
		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical		
Mifepristone		abortion in 1st and 2nd trimesters	APPROVED	21/12/2012
_		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical		
Mifepristone		abortion in 1st and 2nd trimesters	APPROVED	21/12/2013
		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical		
Mifepristone		abortion in 1st and 2nd trimesters	APPROVED	21/12/2013
corticotrophin releasing	Corticorelin (CRH)	as a diagnostic agent during Inferior Petrosal Sinus sampling for confirmation	APPROVED	15/03/201
normone	20. 0.00. 0 (0)	that a patient's excess ACTH production is from the pituitary gland		20,00,201
		evaluation of functional capacity and response of gonadotrophic hormones (LH		
gonadorelin	LHRH (gonadotrophin	and FSH) in adults suspected of pituitary failure or evaluation of delayed	APPROVED	15/03/2013
50	releasing hormones)	and 1 311) in addits suspected of pitultary failure of evaluation of delayed		13,03,201

thyrotropin releasing hormone	Protirelin (TRH)	as an adjunct to other diagnostic procedures in patients with pituitary or hypothalamic dysfunction	APPROVED	14/03/2013
Sodium Benzoate		in patients with: urea cycle disorders, nonketotic hyperglycinaemia and acute neonatal hyperammonaemia due to other metabolic disorders (including organic acidurias, methylmalonic acidaemia and propionic acidaemia)	APPROVED	18/12/2012
cholecalciferol 1.25mg (50,000	D 3-50	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
Mifepristone		Medical abortion in 1st and 2nd trimester (foetal abnormalities, serious/life threatening condition)Cervical Priming prior to surgical abortion in the 1st and 2nd trimesters	APPROVED	21/12/2012
Mifepristone		Medical abortion in 1st and 2nd trimester (foetal abnormalities, serious/life threatening condition)Cervical Priming prior to surgical abortion in the 1st and 2nd trimesters	APPROVED	21/12/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	17/12/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)		for skin prick testing for allergies	APPROVED	17/12/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	18/12/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)		for skin prick testing for allergies	APPROVED	18/12/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	18/12/2012
Melatonin 3mg capsule		patients with a sleep/ wake cycle disturbance	APPROVED	19/12/2012
Mifepristone		for medical abortion in the first trimester	APPROVED	9/01/2013
Mifepristone		for medical abortion in the first trimester	APPROVED	9/01/2013
Mifepristone		for medical abortion in the first trimester	APPROVED	9/01/2013
Perflutren Protein-Type A Microspheres Injectable Suspension	Optison	for use in patients with suboptimal echocardiogram	APPROVED	18/12/2012
Stabilised Ceretec (technetium 99mTc exametazine injection)		for cerebral perfusion imaging, ictal studies and epilepsy	APPROVED	19/12/2012
Stabilised Ceretec (technetium 99mTc exametazine injection)		for cerebral perfusion imaging, ictal studies and epilepsy	APPROVED	19/12/2012
Stabilised Ceretec (technetium 99mTc exametazine injection)		for cerebral perfusion imaging, ictal studies and epilepsy	APPROVED	19/12/2012
Stabilised Ceretec (technetium 99mTc exametazine injection)		for cerebral perfusion imaging, ictal studies and epilepsy	APPROVED	18/12/2012

Stabilised Ceretec (technetium 99mTc exametazine injection)	for cerebral perfusion imaging, ictal studies and epilepsy	APPROVED	18/12/2012
Stabilised Ceretec (technetium 99mTc exametazine injection)	for cerebral perfusion imaging, ictal studies and epilepsy	APPROVED	19/12/2012
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing for allergies	APPROVED	17/01/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)	skin prick testing for allergies	APPROVED	17/01/2013
Estrapel Oestradiol Implant 50mg	management of oestrogen deficiency symptoms due to natural or surgical menopause	APPROVED	15/01/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing for allergies	APPROVED	17/01/2013
Bifidobacterium breve M16 V	prevention of necrolising enterocolitis (NEC) and death in preterm neonates	APPROVED	15/01/2013
melatonin tablets 5 mg	various conditions where sleep patterns are disrupted, such as Rett syndrome, intellectual impairment and autism	APPROVED	15/01/2013
melatonin controlled release capsules 3 mg	various conditions where sleep patterns are disrupted, such as Rett syndrome, intellectual impairment and autism	APPROVED	15/01/2013
melatonin tablets 5mg and melatonin controlled release capsules 3 mg	various conditions where sleep patterns are disrupted, such as Rett syndrome, intellectual impairment and autism	APPROVED	15/01/2013
cholecalciferol	moderate to severe Vitamin D deficiency	APPROVED	15/01/2013
holecalciferol	moderate to severe Vitamin D deficiency	APPROVED	15/01/2013
holecalciferol	moderate to severe Vitamin D deficiency	APPROVED	15/01/2013
orazepam Injection, USP	for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
orazepam Injection, USP	for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
orazepam Injection, USP	for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
orazepam Injection, USP	for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
orazepam Injection, USP	for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
orazepam Injection, USP	for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
orazepam Injection, USP	for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
orazepam Injection, USP	for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
orazepam Injection, USP	for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013

Lorazepam Injection, USP		for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
Lorazepam Injection, USP		for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
Lorazepam Injection, USP		for Sedation/Tranquilisation as indicated in the Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
Lorazepam Injection, USP		for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
Lorazepam Injection, USP		for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
Lorazepam Injection, USP		for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
Lorazepam Injection, USP		for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
cholecalciferol 1.25mg (50,000IU) capsule D3-50	D3-50	moderate to severe Vitamin D deficiency	APPROVED	15/01/2013
cholecalciferol 1.25mg (50,000IU) capsule D3-50	D3-50	moderate to severe Vitamin D deficiency	APPROVED	15/01/2013
cholecalciferol 1.25mg (50,000IU) capsule D3-50	D3-50	moderate to severe Vitamin D deficiency	APPROVED	15/01/2013
cholecalciferol 1.25mg (50,000IU) capsule D3-50	D3-50	moderate to severe Vitamin D deficiency	APPROVED	15/01/2013
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	25/01/2013
Mifepristone		medical abortion in the first trimester	APPROVED	25/01/2013
Mifepristone		medical abortion in the first trimester	APPROVED	25/01/2013
Mifepristone		medical abortion in the first trimester	APPROVED	25/01/2013
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing in allergy testing	APPROVED	30/01/2013
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing in allergy testing	APPROVED	30/01/2013
Multiple Allergens - Alyostal	Alyostal/Stallergenes	for testing of allergies in the management of allergic disease	APPROVED	30/01/2013
Multiple Allergens - Alyostal	Alyostal/Stallergenes	for testing of allergies in the management of allergic disease	APPROVED	30/01/2013
Multiple Allergen Skin Test Reagents (Alyostal)	Alyostal	for therapeutic and diagnostic use.	APPROVED	12/02/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for allergies	APPROVED	12/02/2013
Normal Saline with Phenol Diluents (ALK-Abello NSP)		skin prick testing for allergies	APPROVED	12/02/2013
Diater DAP Penicillin and Amoxycillin Skin Test Reagents	ALK-Abello	for skin prick testing for allergy testing	APPROVED	12/02/2013

Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	for skin prick testing for allergy testing	APPROVED	12/02/2013
Multiple Allergen Skin Test				
Reagents (Alyostal)	Alyostal	for skin prick testing for allergy testing	APPROVED	12/02/2013
Multiple Allergen Skin Test				
Reagents (ALK-Abello)	ALK-Abello	for skin prick testing for allergy testing	APPROVED	12/02/2013
Multiple Allergen Skin Test				
Reagents (Alyostal)	Alyostal	for skin prick testing for allergy testing	APPROVED	12/02/2013
Multiple Allergen Skin Test				
Reagents (ALK-Abello)		skin prick testing for allergies	APPROVED	12/02/2013
Multiple Allergen Skin Test				
Reagents (Alyostal)		skin prick testing for allergies	APPROVED	12/02/2013
Gallium-68 labelled octreotide		Detection of suspected gastroenteropancreatic endocrine tumour; 2.		
analogues (68Ga-DOTATATE,		Exclusion of additional disease sites; 3. Diagnostic localisation of	APPROVED	22/02/2013
68Ga-DOTANOC, 68Ga-		phaeochromocytomas, paragangliomas, ganglioneuroblastomas and		
OOTATOC)		ganglioneuromas: 4. Assessment of tumour burden.		
Gallium-68 labelled octreotide		1. Detection of suspected gastroenteropancreatic endocrine tumour; 2.		
analogues (68Ga-DOTATATE,		Exclusion of additional disease sites; 3. Diagnostic localisation of	APPROVED	22/02/2013
58Ga-DOTANOC, 68Ga-		phaeochromocytomas, paragangliomas, ganglioneuroblastomas and		
DOTATOC)		ganglioneuromas: 4. Assessment of tumour burden.		
Gallium-68 labelled octreotide		1. Detection of suspected gastroenteropancreatic endocrine tumour; 2.		
analogues (68Ga-DOTATATE,		Exclusion of additional disease sites; 3. Diagnostic localisation of	APPROVED	22/02/2013
58Ga-DOTANOC, 68Ga-		phaeochromocytomas, paragangliomas, ganglioneuroblastomas and		
DOTATOC)		ganglioneuromas: 4. Assessment of tumour burden.		
Gallium-68 labelled octreotide		1. Detection of suspected gastroenteropancreatic endocrine tumour; 2.		
analogues (68Ga-DOTATATE,		Exclusion of additional disease sites; 3. Diagnostic localisation of	APPROVED	22/02/2013
68Ga-DOTANOC, 68Ga-		phaeochromocytomas, paragangliomas, ganglioneuroblastomas and	7	,,
DOTATOC)		ganglioneuromas: 4. Assessment of tumour burden.		
Gallium-68 labelled octreotide		1. Detection of suspected gastroenteropancreatic endocrine tumour; 2.		
analogues (68Ga-DOTATATE,		Exclusion of additional disease sites; 3. Diagnostic localisation of	APPROVED	22/02/2013
68Ga-DOTANOC, 68Ga-		phaeochromocytomas, paragangliomas, ganglioneuroblastomas and	ATTROVED	22/02/2013
DOTATOC)		ganglioneuromas: 4. Assessment of tumour burden.		
Gallium-68 labelled octreotide		1. Detection of suspected gastroenteropancreatic endocrine tumour; 2.		
analogues (68Ga-DOTATATE,		Exclusion of additional disease sites; 3. Diagnostic localisation of	APPROVED	22/02/2012
68Ga-DOTANOC, 68Ga-		phaeochromocytomas, paragangliomas, ganglioneuroblastomas and	APPROVED	22/02/2013
DOTATOC)		ganglioneuromas: 4. Assessment of tumour burden.		
ndocyanine Green		retinal angiography in ophthalmic practice	APPROVED	11/04/2013
ndocyanine Green		for use in retinal angiography	APPROVED	22/02/2013
ndocyanine Green		for use in retinal angiography	APPROVED	22/02/2013
ndocyanine Green		for use in retinal angiography	APPROVED	22/02/2013
Melatonin capsules		sleep disturbance in children with developmental disabilities	APPROVED	22/02/2013
		inborn errors of protein metabolism (organic acidaemias), fatty acid oxidation		, ==, = 3 2 3
L-Carnitine (oral and		defects, primary carnitine deficiency, chronic depletion, nutritional deficiency	APPROVED	22/02/2013
intravenous forms)		and cardiomyopathy		, 0_, _01

L-Carnitine (oral and intravenous forms)		inborn errors of protein metabolism (organic acidaemias), fatty acid oxidation defects, primary carnitine deficiency, chronic depletion, nutritional deficiency and cardiomyopathy	APPROVED	22/02/2013
cholecalciferol IM injection 100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	1/03/2013
cholecalciferol IM injection 300,000 IU/mL (Vitamine D3 Steuli)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	4/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	Multiple allergen extracts	skin prick testing for allergic diseases	APPROVED	8/03/2013
cholecalciferol 1.25mg (50,000IU)	Cal D Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	1/03/2013
cholecalciferol 1.25mg (50,000IU)	Cal D Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	1/03/2013
cholecalciferol 1.25mg (50,000IU)	Cal D Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	1/03/2013
cholecalciferol 1.25mg (50,000IU)	Cal D Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	21/03/2013
cholecalciferol 1.25mg (50,000IU)	Cal D Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	1/03/2013
cholecalciferol 1.25mg (50,000IU)	Cal D Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	24/04/2013
PEG-asparaginase		for treatment of children with acute lymphoblastic leukaemia	APPROVED	5/03/2013
Indocyanine Green		for retinal angiography	APPROVED	8/03/2013
Moorfields phenylephrine 0.6% intracameral syringe		for floppy iris syndrome in patients undergoing cataract surgery	APPROVED	8/03/2013
Moorfields phenylephrine 0.6% intracameral syringe		for floppy iris syndrome in patients undergoing cataract surgery	APPROVED	8/03/2013
Moorfields phenylephrine 0.6% intracameral syringe		for floppy iris syndrome in patients undergoing cataract surgery	APPROVED	8/03/2013
Indocyanine Green		for retinal angiography	APPROVED	8/03/2013
Indocyanine Green		for retinal angiography	APPROVED	8/03/2013
Glycopyrrolate 1mg tablets		treatment of excessive salivation and drooling (sialorrhoea) in patients with advanced neuromuscular disease	APPROVED	5/03/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for allergies	APPROVED	8/03/2013
Glycopyrrolate 1mg tablets		for control of excessive salivary secretions in children with developmental disabilities	APPROVED	5/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	8/03/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	for skin prick testing for allergy testing	APPROVED	16/05/2013
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergy testing	APPROVED	16/05/2013

Diater DAP Penicillin and Amoxycillin Skin Test Reagents		for skin prick testing for allergy testing	APPROVED	16/05/2013
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	15/03/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		for skin prick testing for allergies	APPROVED	15/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	15/03/2013
cholecalciferol 1.25mg (50,000 IU)	D-3-50, Cal-D-Forte	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000 IU)	D-3-50, Cal-D-Forte	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000 IU)	D-3-50, Cal-D-Forte	moderate to severe vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000	D-3-50, Cal-D-Forte	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000 IU)	D 3-50	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000	D 3-50	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000 IU)	D 3-50	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000 IU)	D 3-50	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000	D 3-50	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000 IU)	D 3-50	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	21/03/2013
Diater DAP Penicillin and Amoxycillin Skin Test Reagents		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Indocyanine Green		measurement of ICG retention (liver function) using Pulsion Limon Monitor	APPROVED	21/03/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing to diagnose allergies	APPROVED	21/03/2013
flunarizine		neurological conditions such as migrane, hemiplegia, cerebral vasculopathy and Moya Moya Syndrome	APPROVED	21/03/2013
Diater DAP Penicillin and Amoxycillin Skin Test Reagents		skin prick testing to diagnose allergies	APPROVED	26/03/2013

Diater DAP Penicillin and Amoxycillin Skin Test Reagents	skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	skin prick testing for allergies	APPROVED	16/05/2013
cholecalciferol 1.25mg (50,000IU)	moderate to severe Vitamin D deficiency	APPROVED	4/04/2013
ndocyanine Green	during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	4/04/2013
Cholecalciferol 1.25 mg (50,000IU)	moderate to severe Vitamin D deficiency	APPROVED	5/04/2013
Diater DAP Penicillin and Amoxycillin Skin Prick Test	skin prick testing for diagnosis of penicillin and amoxycillin allergies	APPROVED	4/04/2013
Reagents Multiple Allergen Skin Test Reagents (ALK-Abello)	skin prick testing for diagnosis of allergies	APPROVED	4/04/2013

Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for diagnosis of allergies	APPROVED	4/04/2013
Multiple Allergen Skin Test				
Reagents (Alyostal)		skin prick testing for diagnosis of penicillin allergy	APPROVED	4/04/2013
Multiple Allergen Skin Test			10000150	1/01/0010
Reagents (Alyostal)	Alyostal	skin prick testing for diagnosing allergies	APPROVED	4/04/2013
Multiple Allergen Skin Test		akin nyiek taating fay diagnasing allaygies	ADDDOVED	4/04/2012
Reagents (Alyostal)		skin prick testing for diagnosing allergies	APPROVED	4/04/2013
Multiple Allergen Skin Prick Test	Alvostal	skin prick testing for diagnostic allegy testing	APPROVED	11/04/2013
Reagents (Alyostal)	Aiyostai	skin prick testing for diagnostic anegy testing	AITROVED	11/04/2013
Cholecalciferol 1.25 mg		moderate to severe Vitamin D deficiency	APPROVED	20/05/2013
(50,000IU)		moderate to severe vitalinia b denote ity	711110725	20,03,2013
Cholecalciferol 1.25 mg		moderate to severe Vitamin D deficiency	APPROVED	20/05/2013
(50,000IU)		,		,,
cholecalciferol 1.25mg (50,000	Cal.D.Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	30/05/2013
IU)	,	,		
cholecalciferol 1.25mg (50,000	Cal.D.Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	20/05/2013
IU)		· ·		
cholecalciferol IM injection		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
100,000 IU/mL (D3-Vicotrat)				
cholecalciferol IM injection		25 by descrip D deficiency (common 25 by description D (20 mon 1/1))	ADDDOVED	15/05/2017
300,000 IU/mL (Vitamine D3		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
Streuli) cholecalciferol IM injection				
100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
cholecalciferol IM injection				
300,000 IU/mL (Vitamine D3		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
Streuli)		Severe vitaliin b deficiency (serain 25 flydroxyvitaliin b 150fillio), Ej	AITROVED	13/03/2013
cholecalciferol IM injection				
100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
cholecalciferol IM injection				
300,000 IU/mL (Vitamine D3		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
Streuli)				., ,
cholecalciferol IM injection				. = /a= /a a . a
100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
cholecalciferol IM injection				
300,000 IU/mL (Vitamine D3		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
Streuli)				
cholecalciferol IM injection		covere Vitamin D deficiency (corum 35 hydrovy ditamin D 320 1/1)	ADDDOVED	15/05/2012
100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
cholecalciferol IM injection				
300,000 IU/mL (Vitamine D3		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
Streuli)				

cholecalciferol IM injection		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
100,000 IU/mL (D3-Vicotrat)		Severe vitalini b denotency (serain 25 hydroxyvitalini b (56iiii)), 2)	ATTROVED	13/03/2013
cholecalciferol IM injection				
300,000 IU/mL (Vitamine D3		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
Streuli)				
cholecalciferol IM injection		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
100,000 IU/mL (D3-Vicotrat)			-	-,,
cholecalciferol IM injection				
300,000 IU/mL (Vitamine D3		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
Streuli)				
melatonin oral liquid 1mg/mL		to treat sleep disturbances in children and adolescents with mental problems	APPROVED	16/05/2013
		where sleep hygeine trials have failed	-	-,,
melatonin oral liquid 1mg/mL		to treat sleep disturbances in children and adolescents with mental problems	APPROVED	16/05/2013
		where sleep hygeine trials have failed	-	-,,
melatonin oral liquid 1mg/mL		to treat sleep disturbances in children and adolescents with mental problems	APPROVED	16/05/2013
, , , , ,		where sleep hygeine trials have failed	-	-,,
melatonin oral liquid 1mg/mL		to treat sleep disturbances in children and adolescents with mental problems	APPROVED	16/05/2013
, , , , ,		where sleep hygeine trials have failed	-	-,,
melatonin oral liquid 1mg/mL		to treat sleep disturbances in children and adolescents with mental problems	APPROVED	16/05/2013
		where sleep hygeine trials have failed	-	-,,
melatonin oral liquid 1mg/mL		to treat sleep disturbances in children and adolescents with mental problems	APPROVED	16/05/2013
		where sleep hygeine trials have failed		-,,
melatonin oral liquid 1mg/mL		to treat sleep disturbances in children and adolescents with mental problems	APPROVED	16/05/2013
,		where sleep hygeine trials have failed		
5 Methoxypsoralen	Pentaderm	for treatment of psoriasis and vitiligo	APPROVED	15/05/2013
(Pentaderm) tablets				
Dydrogesterone (Duphaston)		for uterine protection while on Oestrogen	APPROVED	16/05/2013
10mg		<u> </u>		
Progesterone (Utrogestan)		for uterine protection while on Oestrogen	APPROVED	16/05/2013
100mg and 200mg	C-1-if Ct 10000			
cholecalciferol 1.25mg	Calciferol Strong, 10000-	hypovitaminosis D	APPROVED	20/05/2013
(50,000IU)	50000 IU/day			
Multiple Allergen Skin Test	Stallergens	for skin prick allergy testing	APPROVED	16/05/2013
Reagents (Alyostal)				
Lorazepam 2mg/mL vial		for the management of acute arousal and agitation in patients who are	APPROVED	16/05/2013
		admitted with an acute psychosis		
Lorazepam 2mg/mL vial		for the management of acute arousal and agitation in patients who are	APPROVED	16/05/2013
		admitted with an acute psychosis		
Lorazepam 2mg/mL vial		for the management of acute arousal and agitation in patients who are	APPROVED	16/05/2013
		admitted with an acute psychosis	+	
Lorazepam 2mg/mL vial		for the management of acute arousal and agitation in patients who are	APPROVED	16/05/2013
		admitted with an acute psychosis	+	
Lorazepam 2mg/mL vial		for the management of acute arousal and agitation in patients who are	APPROVED	16/05/2013
		admitted with an acute psychosis		

Lorazepam 2mg/mL vial		for the management of acute arousal and agitation in patients who are admitted with an acute psychosis	APPROVED	16/05/2013
orazepam 2mg/mL vial		for the management of acute arousal and agitation in patients who are admitted with an acute psychosis	APPROVED	16/05/2013
orazepam 2mg/mL vial		for the management of acute arousal and agitation in patients who are admitted with an acute psychosis	APPROVED	16/05/2013
orazepam 2mg/mL vial		for the management of acute arousal and agitation in patients who are admitted with an acute psychosis	APPROVED	16/05/2013
orazepam 2mg/mL vial		for the management of acute arousal and agitation in patients who are admitted with an acute psychosis	APPROVED	16/05/2013
.orazepam 2mg/mL vial		for the management of acute arousal and agitation in patients who are admitted with an acute psychosis	APPROVED	16/05/2013
orazepam 2mg/mL vial		for the management of acute arousal and agitation in patients who are admitted with an acute psychosis	APPROVED	16/05/2013
Lorazepam 2mg/mL vial		for the management of acute arousal and agitation in patients who are admitted with an acute psychosis	APPROVED	16/05/2013
Lorazepam 2mg/mL vial		for the management of acute arousal and agitation in patients who are admitted with an acute psychosis	APPROVED	16/05/2013
Pipothiazine 50mg/mL depot njection (Piportil)	Piportil	for the treatment of psychosis in patients who have experienced problematic side effects with the currenlty available depot injections	APPROVED	16/05/2013
Pipothiazine 50mg/mL depot njection (Piportil)	Piportil	for the treatment of psychosis in patients who have experienced problematic side effects with the currenlty available depot injections	APPROVED	16/05/2013
Pipothiazine 50mg/mL depot njection (Piportil)	Piportil	for the treatment of psychosis in patients who have experienced problematic side effects with the currenlty available depot injections	APPROVED	16/05/2013
Pipothiazine 50mg/mL depot njection (Piportil)	Piportil	for the treatment of psychosis in patients who have experienced problematic side effects with the currenlty available depot injections	APPROVED	16/05/2013
Pipothiazine 50mg/mL depot njection (Piportil)	Piportil	for the treatment of psychosis in patients who have experienced problematic side effects with the currenlty available depot injections	APPROVED	16/05/2013
Pipothiazine 50mg/mL depot njection (Piportil)	Piportil	for the treatment of psychosis in patients who have experienced problematic side effects with the currenlty available depot injections	APPROVED	16/05/2013
Pipothiazine 50mg/mL depot njection (Piportil)	Piportil	for the treatment of psychosis in patients who have experienced problematic side effects with the currenlty available depot injections	APPROVED	16/05/2013
Pipothiazine 50mg/mL depot njection (Piportil)	Piportil	for the treatment of psychosis in patients who have experienced problematic side effects with the currenlty available depot injections	APPROVED	16/05/2013
Pipothiazine 50mg/mL depot njection (Piportil)	Piportil	for the treatment of psychosis in patients who have experienced problematic side effects with the currenlty available depot injections	APPROVED	16/05/2013
ipothiazine 50mg/mL depot njection (Piportil)	Piportil	for the treatment of psychosis in patients who have experienced problematic side effects with the currenlty available depot injections	APPROVED	16/05/2013
Pipothiazine 50mg/mL depot njection (Piportil)	Piportil	for the treatment of psychosis in patients who have experienced problematic side effects with the currenlty available depot injections	APPROVED	16/05/2013
Pipothiazine 50mg/mL depot njection (Piportil)	Piportil	for the treatment of psychosis in patients who have experienced problematic side effects with the currenlty available depot injections	APPROVED	16/05/2013
Pipothiazine 50mg/mL depot njection (Piportil)	Piportil	for the treatment of psychosis in patients who have experienced problematic side effects with the currenlty available depot injections	APPROVED	16/05/2013

Pipothiazine 50mg/mL depot injection (Piportil)	Piportil	for the treatment of psychosis in patients who have experienced problematic side effects with the currenlty available depot injections	APPROVED	16/05/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for diagnostic allergy testing	APPROVED	28/06/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for diagnostic allergy testing	APPROVED	28/06/2013
Diater DAP Skin Test Reagents		skin prick testing for diagnostic allergy testing	APPROVED	28/06/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for diagnostic allergy testing	APPROVED	31/05/2013
Multiple Allergen Skin Prick Test Reagents (ALK-Abello)		for skin prick testing for diagnostic allegy testing	APPROVED	28/06/2013
Multiple Allergen Skin Prick Test Reagents (Alyostal)	Alyostal	for skin prick testing for diagnostic allegy testing	APPROVED	28/06/2013
Diater DAP Skin Prick Test Reagents		for skin prick testing for diagnostic allegy testing	APPROVED	28/06/2013
DAP-kit [penicilloyl-poly-L (PPL) and minor determinant mixture MDM)] and Clavulanic acid		skin prick testing for diagnostic allergy testing	APPROVED	28/06/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for diagnostic allergy testing	APPROVED	28/06/2013
Diater DAP Penicillin and Amoxycillin Skin Test Reagents		skin prick testing for allergy testing	APPROVED	31/05/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for allergy testing	APPROVED	31/05/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergy testing	APPROVED	31/05/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergy testing	APPROVED	5/06/2013
Multiple Allergen Skin Test Reagents (Alyostal)	Alyostal	for skin prick testing to identify allergies	APPROVED	16/05/2013
Penicillin Allergenic Determinants (PAD)		for the diagnosis of penicillin allergic reactions	APPROVED	31/05/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	5/06/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for allergies	APPROVED	5/06/2013
Diater DAP Penicillin and Amoxycillin SkinTest Reagents		skin prick testing for allergies	APPROVED	5/06/2013
urokinase		thrombolysis of occluded vein and prosthetic grafts, arteriovenous dialysis fistulas and during endovascular recanalisation	APPROVED	18/06/2013

Multiple Allergen Skin Test	ALK Abello	for skin prick testing for allergies	APPROVED	31/05/2013
Reagents (ALK-Abello)	/ LEK / IDENO	Tot skill prick testing for unergies	711110125	31,03,2013
Multiple Allergen Skin Test	Alyostal	for skin prick testing for allergies	APPROVED	31/05/2013
Reagents (Alyostal)	, y e sta.	Tot skill priok testing for unergies	7.1.1.10.125	31,03,2013
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
0.6% Intracameral Syringe		ior ase in rioppy in a synarome in patients and rigoring editarder sangery	7.1.1.10.125	30,03,2013
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
0.6% Intracameral Syringe		ior ase in rioppy in a synarome in patients and rigoring editarder sangery	7.1.1.10.125	
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
0.6% Intracameral Syringe		ior ase in rioppy in a syndrome in patients and rigoring editarder sangery	711110125	30,03,2013
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
0.6% Intracameral Syringe		tor use in rioppy in a syndrome in patients undergoing educate surgery	711110125	30,03,2013
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
0.6% Intracameral Syringe		tor use in rioppy in a syndrome in patients undergoing educate surgery	711110125	30,03,2013
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
0.6% Intracameral Syringe				
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
0.6% Intracameral Syringe				
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
0.6% Intracameral Syringe		tor use in rioppy in s syndrome in patients undergoing editarties sargery	ATTROVED	30,03,2013
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
0.6% Intracameral Syringe		tor use in rioppy in s syndrome in patients undergoing cutaract sargery	AITHOVED	30/03/2013
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
0.6% Intracameral Syringe		tor use in rioppy in s syndrome in patients undergoing catalact surgery	ALLINOVED	30/03/2013
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
0.6% Intracameral Syringe		tor use in rioppy in s syndrome in patients undergoing editarties sargery	ATTROVED	30,03,2013
Moorefields Phenylephrine		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
0.6% Intracameral Syringe		tor use in rioppy in s syndrome in patients undergoing catalact surgery	ALLINOVED	30/03/2013
Bifidobacterium Bifidum &		pretern neonates born 32 weeks of gestation, for prevention of necrotising enterocolitis (NEC) and mortality	APPROVED	4/06/2013
actobacillus Acidophilus	Infloran			
Infloran)		enterocontis (NEC) and mortality		
ndocyanine Green		for use during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	5/06/2013
Diphencyprone (DPCP)	diphenycyclopropenone	Melanoma recurrent in the skin or metastatic to the skin	APPROVED	4/06/2013